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ABSTRACT OF THE DISSERTATION
Influence of Human Papillomvirus 16 E6 on
TRAIL-mediated Apoptosis
by
Theodore O. Garnett
Doctor of Phi losophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, May 2006
Penelope Duerksen-Hughes, Chairperson
Viruses have developed sophisticated strategies to evade host defenses and
facilitate the production and spread of progeny.

HPV 16, whose immune evasion

activities can contribute to cervical cancer, is a prime example of such a virus. In this
study, we examined the influence of HPV 16 E6 on TRAIL-induced FADD-dependent
and -independent pathways in two cellular models: HCT116 colon carcinoma cells and
U20S osteosarcoma cells. We show that transfection of the HPV 16 E6 oncogene into
HCT116 cells provides protection from TRAIL-mediated apoptosis.

Additionally, we

demonstrate that the protection provided by E6 is dose-dependent because higher levels
of E6 provide greater protection. The mechanism underlying this protection involves a
rapid reduction in the protein levels of both FADD and procaspase-8, which results in
suppression of the activation of caspases 8, 3 and 2. Interestingly, E6 does not interfere
with the mitochondrial apoptotic pathway even though HCT116 cells have been
classified as type II cells with regard to TRAIL signaling.
To further explore the mechanisms of TRAIL-induced cell death, we used E6 as a
molecular tool to probe the TRAIL pathway in U20S cells. Intriguingly, we found that
while E6 protected HCT116 cells from TRAIL, U20S cells containing E6 remained
sensitive to TRAIL.

Furthennore, silencing FADD and procaspase-8 expression with

1

siRNA did not prevent TRAlL-induced apoptosis in U20S cells.

However, siBid

provided significant protection from TRAIL in these cells, and the cleavage kinetics of
Bid and caspase-8 revealed that Bid was cleaved prior to the activation of caspase-8 in
this cell death cascade. Although Bid cleavage has been implicated in the JNK and
ceramide pathways, neither pathway was found to contribute to TRAlL-induced
apoptosis in U20S cells.

However, analysis of cathepsin B activity in these cells

revealed that it was significantly activated after exposure to TRAIL. Additionally, the
cathepsin B inhibitor, CA074Me, inhibited TRAIL-mediated apoptosis and delayed the
cleavage of Bid in U20S cells exposed to TRAIL.

Taken together, these findings

demonstrate that TRAIL triggers a FADD-dependent pathway in HCT116 cells and a
FADD-independent pathway in U20S cells, and that the ability of E6 to influence
TRAlL-induced apoptosis dependents on which pathway predominates.
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CHAPTER ONE
INTRODUCTION
TRAIL and its Receptors
Recently, interest in death receptor-mediated apoptosis in cancer cells has grown
substantially because current therapies that damage the DNA of these cells and trigger
p53-dependent apoptosis are most effective in cancer cells that express wild-type p53,
which account for only about 50% of human cancers. For this reason, alternative (p53independent) mechanisms of inducing apoptosis in cancer cells hold therapeutic potential.
Death receptors belong to the tumor necrosis factor (TNF) receptor superfamily
and interact with ligands in the TNF superfamily.

The receptors that comprise TNF

receptor superfamily include TNF-receptor 1 (TNF-R1), Fas, death receptor 4 (DR4) and
death receptor 5 (DR5), which bind to their cognate ligands TNF, Fas ligand (FasL) and
TNF-related apoptosis inducing ligand (TRAIL)/Apo2L, respectively. The TRAIL death
receptor pathway has gained significant attention because of the ability of TRAIL to
preferentially induce cell death in many tumor cell lines but not in most normal cells
(Walczak et al., 1999).

TRAIL was identified entirely on the basis of sequence

homology with other members of the TNF superfamily, particularly FasL (Wiley et al..
1995). TRAIL is expressed as a type II membrane protein, however, its extracellular
domain can be proteolytically cleaved to generate a soluble fonn of the ligand (Wajant et
al., 2001). TRAIL binds to five receptors (reviewed in Kimberley & Screaton, 2004,
reviewed in LeBlanc & Ashkenazi, 2003). Two of these receptors, DR4 (TRAIL-R1)
(Pan et al., 1997b) and DR5 (TRAIL-R2) (Pan et al., 1997a) possess a conserved death
domain (DD) motif which mediates both homo and heterotypic interactions and are thus
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capable of engaging signaling proteins in the caspase activation pathway. However, the
other three receptors are not capable of transmitting death signals from TRAIL. DcRl
(decoy receptor 1 or TRAIL-R3) (Degli-Esposti et al., 1997) lacks both transmembrane
and DDs and DcR2 (decoy receptor 2 or TRAIL-R4) (Marsters et al., 1997) has a
truncated, nonfunctional death domain. These receptors were tenned ‘decoy receptors’
because they could compete with DR4 and DR5 for binding to TRAIT, when
overexpressed (Sheridan et al., 1997). Unlike its counterparts, the fifth receptor,
osteoprotegerin (OPG), is soluble and does not bind as strongly to TRAIL at
physiological temperatures (Emery et al., 1998). The soluble form of TRAIL is primarily
derived from activated monocytes and neutrophils (Tecchio et al., 2004) while the
TRAIL receptors are expressed on most cell types (Gaur, 2003).

Apoptotic Signaling by TRAIL
TRAIL-induced apoptosis is initiated by the binding of TRAIL to DR4 and/or
DR5.

TRAIL forms a homotrimer (Mongkolsapaya et al., 1999) and associates with

three receptor monomers. This leads to the recruitment of adaptor proteins and initiator
caspases to the death domains (DD) of the receptors and the formation of a death
inducing signaling complex (DISC). Until recently, the exact composition of the TRAIL
DISC was unknown due to conflicting reports in the literature regarding the role of
certain intracellular signaling proteins in the TRAIL apoptotic pathway. By far, the most
controversial of these proteins has been the adaptor protein Fas-associated death domain
(FADD).

Soon after the TRAIL receptors were discovered, several groups using co-

transfection/co-immunoprecipitation techniques were unable to demonstrate binding
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between FADD and DR4 or DR5 (MacFarlane et al., 1997, Pan et al., 1997a, Pan et al.,
1997b, Sheridan et al., 1997), while similar experiments by other groups were successful
(Chaudhary et ah, 1997, Schneider et ah, 1997). Adding to the controversy was the
discovery by Yeh and coworkers that FADD deficient fibroblasts were sensitive to DR4induced apoptosis, suggested that FADD was not essential for signal transduction from
DR4 (Yeh, 1998). Flowever, evidence from several groups that isolated the native TRAIL
DISC from untransfected cells, confinned the participation of both FADD and caspase 8
in the apical events of the TRAIL apoptotic pathway (Kischkel et al., 2000, Sprick et al.,
2000). Additionally, another initiator caspase with high homology to caspase 8, caspase
10, was shown to be recruited to the TRAIL DISC, but only in the absence of caspase 8
(Kischkel et al., 2001).

Both caspases 8 and 10 are activated by autoproteolysis,

resulting in their cleavage and dissociation from the DISC, and the commencement of
downstream events in the cell death pathway (Almasan & Ashkenazi, 2003).
The TRAIL apoptotic pathway is propagated in a manner similar to that described
for Fas. As in the Fas model, cells can either be type I (utilize extrinsic pathway alone)
or type II (utilize both extrinsic and intrinsic pathways) with regard to their response to
TRAIL (Ozoren & El-Deiry, 2002). In type I cells, DISC formation is robust and caspase
8 directly activates caspase 3 which in turn cleaves intracellular substrates such as
poly(ADP-ribose) polymerase (PART) and Lamin B. In contrast, DISC formation in type
II cells is weak and caspase 8 cleaves Bid leading to the activation of the mitochondrial
pathway. The main event in the mitochondrial pathway is the release of cytochrome c
which fonns a complex with Apaf-1 and pro-caspase 9 called the apoptosome. The
formation of the apoptosome leads to the activation of caspase 9 which in turn activates
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caspase 3. Although the type I/II model for TRAIL bears many similarities to the one
described for Fas, apoptotic signaling by TRAIL does not always mirror the Fas model.
For instance, the overexpression of Bcl-2 protects type II cells from Fas-mediated
apoptosis. However, Bcl-2 overexpression in Jurkat cells (a type II cell line) did not
prevent TRAIL-mediated apoptosis even though the mitochondria were only partially
activated (Keogh et al., 2000, Walczak et al., 2000). The importance of the type I/II
mechanism in the TRAIL pathway warrants further investigation since knowledge of the
mechanism a particular cancer cell type prefers can be exploited for therapeutic
intervention. Recently, a relatively obscure initiator caspase, caspase 2, was shown to
play an important role in TRAIL-induced apoptosis in several cell lines (Wagner et al
2004).

In this study, caspase 2 expression was down-regulated by small interfering

(si)RNA which lead to the inhibition of cell death mediated by TRAIL. The study also
found that caspase 2 played a role in Bid cleavage in some cell lines, placing it upstream
in the pathway.

Alternative Cell Death Pathways Triggered by TRAIL
Since Kischkel et al. and Sprick et al. published reports in 2000 showing that both
FADD and caspase 8 are recruited to the TRAIL DISC in untransfected cells (Kischkel et
al., 2000, Sprick et al., 2000), there has been very little debate in the literature regarding
the involvement of alternative intracellular signaling molecules in the TRAIL pathway.
Interestingly, it was shown that mice expressing a dominant negative form of FADD
(FADD-DN) or mice lacking caspase 8 due to the expression of the CnnA transgene did
not have any abnormalities in negative selection (Smith et al., 1996, Walsh et al., 1998).
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Therefore, if TRAIL plays an important role in the negative selection of thymocytes, as
has been suggested (Lamhamedi-Cherradi et ah, 2003), it does so by an alternative
mechanism (FADD/caspase 8 independent) and not by the conventional pathway.
An alternative cell death mechanism that may be activated in response to TRAIL
stimulation is the c-Jun MH2-terminal kinase (INK) pathway. TRAIL has been shown in
a number of studies to activate the INK pathway (Hu et al., 1999, Lin et al., 2000,
Muhlenbeck et al., 1998, Vivo et al., 2003) and there is strong evidence that JNK can
transduce pro-apoptotic signals (Chen et al., 1998, Chen et al., 1996b, Luo et al., 1998,
Okuno et al., 2004, Toumier et al., 2000, Verheij et al., 1996). Intriguingly, several
studies have found that JNK deficiency can result in defects in thymocyte apoptosis
(Rincon et al., 1998, Sabapathy et al., 1999). Activation of the JNK pathway by TRAIL
is believed to involve the recruitment of the adaptor protein TNF associated death domain
(TRADD), followed by the recruitment of receptor interacting protein (RIP) and TNF
receptor associated factor (TRAF)-2 (Hu et al., 1999, Lin et al., 2000).

Studies in

transfected cells have shown that both TRADD and RIP can interact with DR4 and DR5
(Chaudhary et al., 1997) and in a recent study, a small amount of TRAF-2 was found to
associate with DR5 in Jurkat cells (Harper et al., 2003). The recruitment of TRAF-2 can
lead to the acti vation of JNK and its subsequent signaling via the MEKK/MKK4 pathway
or the activation of NF-kappa B and its subsequent signaling via the NIK/IKK pathway
(Hu et al., 1999). Whereas the latter causes the up-regulation of pro-survival genes
(reviewed in Karin & Lin, 2002), the fonner may result in the phosphorylation of c-Jun
and the transacti vation of pro-apoptotic genes such Bax, which can then induce apoptosis
via the mitochondrial pathway (Whitfield et al., 2001). JNK can inhibit anti-apoptotic
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proteins such Bcl-2 (Maundrell et al., 1997) and Bcl-xL (Kharbanda et al., 2000) by
direct phosphorylation, which can also lead to the activation of the mitochondrial
pathway. Additionally, Muhlenbeck and coworkers reported that TRAIL can trigger .INK
activation by both caspase-dependent and independent mechanisms (Muhlenbeck et al.,
1998).

In their study, TRAIL-induced JNK activation was found to be sensitive to

benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (z-VAD-fmk) in HeLa cells
but not Kym-1 cells, indicating a cell type-specific mode of JNK activation. However, in
this and other studies, JNK activation was not found to be sufficient to induce apoptosis
(Lin et al., 2000), although the inhibition of JNK activation after cells were treated with
TRAIL and etoposide prevented the cells from undergoing apoptosis (Vivo et al., 2003).
Therefore, it remains to be determined whether the primary purpose of TRAIL-mediated
JNK activation is to amplify the main signaling pathway in a cell type-specific manner or
whether JNK activation by TRAIL is sufficient and necessary to induce apoptosis in
some cell types but not others.

Modulators of TRAIL Cytotoxicity
Not all cancer cell lines are sensitive to TRAIL. Thus, in some in vitro studies
agents such as the protein synthesis inhibitor cycloheximide (CHX) have been used in
combination with TRAIL to potentiate the induction of cell death (Kumar-Sinha et al..
2002, van Geelen et al., 2003, Wajant et al., 2000). Although the mechanisms of TRAIL
resistance are not completely understood, recent findings on the actions of a number of
molecules have shed some light on this problem, hi some melanoma cell lines, for
example, the X-linked inhibitor of apoptosis protein (XIAP)-mediated repression of
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caspase 3 activity is associated with resistance to TRAIL-induced apoptosis (Hersey &
Zhang, 2001). In TRAIL sensitive melanoma cells, mitochondrial activation leads to the
production of Smac/DIABLO, which inhibits the action of XIAP (Zhang et al., 2001).
Since the levels of XIAP are virtually equivalent between TRAIL sensitive and resistant
cell lines, the amount of Smac/DIABLO produced after the initiation of cell death signals
by TRAIL may detennine the fate of the cell (Almasan & Ashkenazi, 2003). A well
characterized inhibitor of apoptosis is c-FLIP (FLICE-inhibitory protein).

c-FLIP is

closely related to both caspase 8 and 10, but lacks their proteolytic ability (Tschopp et al.,
1998).

The recruitment of caspases 8 and 10 to the TRAIL DISC led to the suggestion

that c-FLIP might inhibit apoptosis triggered by TRAIL, and indeed, some studies have
shown a correlation between c-FLIP and TRAIL resistance (Griffith et al., 1998, Kim et
al., 2000). However, other studies have yielded contradictory results (Mitsiades et al.,
2002, Zhang et al., 2001).

Thus the exact role of c-FLIP in resistance to TRAIL

cytotoxicity remains to be detennined.

Two other likely mediators of resistance to

TRAIL-induced apoptosis are DcRl and DcR2, since they are able to bind to TRAIL
with high affinity and prevent it from transmitting apoptotic signals via DR4 and DR5.
Though many normal cells express at least one decoy receptor, no correlation has been
found between TRAIL resistance and the differential expression of DcRl and/or DcR2
(Hao et al., 2004). It has also been proposed that the transcription factor nuclear factor
Kappa B (NF-Kappa B) may play an important role in resistance to TRAIL cytotoxicity
since it can induce the expression of c-FLIP, Bcl-xL and XIAP (LeBlanc & Ashkenazi,
2003). However, the activation of NF-kappa B by TRAIL is delayed, occurring 4 hours
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after the addition of TRAIL (Kumar-Sinha et ah, 2002) and thus is believed to only play a
limited role in resistance to TRAIL-mediated apoptosis (LeBlanc & Ashkenazi, 2003).

TRAIL: Physiological Role and Therapeutic Potential
Since its discovery, many studies have attempted to define a physiological role for
TRAIL. A number of these studies have pointed to a possible role for TRAIL in immune
surveillance due, in part, to its potent anti-tumor activity (Almasan & Ashkenazi, 2003).
And indeed, it is well-known that TRAIL induces apoptosis in a wide variety of cancer
cell lines (Ashkenazi et ah, 1999, Walczak et ah, 1999). Evidence from studies in mice
also lend support to the role of TRAIL in immune surveillance. For example, TRAILdeficient mice were found to be more susceptible to tumor metastasis that wild-type mice
(Cretney et ah, 2002). Another study demonstrated that the cytotoxicity of liver natural
killer (NK) cells was significantly attenuated in vitro when TRAIL expression was
blocked, while in vivo, blocking the expression of TRAIL caused TRAIL-sensitive cell
lines to spread more aggressively in the liver (Takeda et ah, 2001). However, the results
of experiments in TRAlL-deficient mice should be examined with the understanding that
the biology of the TRAIL system may differ significantly between humans and mice
since there is only one TRAIL receptor in mice, homologous to both DR4 and DR5 (Wu
et ah, 1999). To the chagrin of many scientist in the field of tumor biology, several
studies suggest that a number of normal cell types, particularly hepatocytes (Jo et ah,
2000), may be sensitive to modified recombinant forms of human TRAIL (MartinVillalba et ah, 1999, Simon et ah, 2001, Taimr et ah, 2003). To some degree, these
findings have mitigated enthusiasm in TRAIL as a potential cancer therapeutic
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(Kimberley & Screaton, 2004). Nevertheless, other studies have shown that higher-order
oligmeric and epitope-tagged fonns of TRAIL induce much stronger signals than
unmodified versions of the ligand (Almasan & Ashkenazi, 2003). It has also been shown
that TRAIL requires a Zn atom bound by cysteine in the trimeric ligand for stability and
optimally biological activity (Almasan & Ashkenazi, 2003, Jo et al., 2000).

Thus,

preparations of TRAIL that do not contain the correct proportion of Zn have been
observed to have reduced solubility and the tendency to aggregate, which may account
for the reported cytotoxicity of some versions of TRAIL in normal adult cells (Jo et al..
2000, Lawrence et al., 2001).

Due to the potential cytotoxicity of TRAIL to

untransformed cells, efforts are ongoing to develop agonistic antibodies to DR4 and DR5
that are capable of activating the TRAIL pathway in tumor cells while minimizing or
eliminating adverse effects to normal cells. Monoclonal antibodies to TRAIL-R2 show
promise in mouse models and have entered Phase I clinical trials (Fischer & SchulzeOsthoff, 2005).
Another characteristic of TRAIL that is often presented as evidence of its putative
role in immune surveillance is its anti-viral activity (Strater & Moller, 2004). TRAIL is
expressed on a variety of cells involved in host defense against viral infection including
NK cells (Sato et al., 2001, Zamai et al., 1998), cytotoxic T cells (Jeremias et al., 1998,
Kayagaki et al., 1999b), monocytes/macrophages (Griffith et al., 1999) and dendritic cells
(Fanger et al., 1999). Another clue to TRAIL’S involvement in immune surveillance is
its relationship with the interferons (IFNs), particularly IFN-y.

Type I and type II

interferons play a critical role in the immune system’s response to viral infection and are
known to induce the expression of TRAIL on a number of different cell types (Fanger et
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al., 1999, Kayagaki et al., 1999a). Additionally, TRAIL is one of the earliest genes
induced by IFN-P and is believed to mediate its anti-tumor and anti-viral activities
(Almasan & Ashkenazi, 2003).

Some cell types also show increased sensitivity to

TRAIL following viral infection.

For example, cytomegalovirus (CMV)-infected

fibroblasts are more sensitive to TRAIL-induced apoptosis than their non-infected
counterparts (Sedger et al., 1999). Not surprisingly, viruses have developed sophisticated
strategies to appropriate and to combat cellular responses to TRAIL.

For instance.

infection with human immunodeficiency virus-1 (HIV-1) can trigger the expression of
TRAIL in monocytes, contributing to HIV-1 pathogenesis by inducing CD4(+) T cell
death (Herbeuval et al., 2005) and exogenous HIV tat has been shown to protect cells
from TRAIL-mediated apoptosis by decreasing the levels of caspase-10 mRNA and
protein (Gibellini et al., 2001). Human papillomavirus (F1PV) 16 E5 has also been shown
to protect cells from both Fas and TRAIL-induced apoptosis, albeit by different
mechanisms (Kabsch & Alonso, 2002). In their study Kabsch and Alonso showed that
E5 inhibits Fas-induced apoptosis, in part, by decreasing the cell surface expression of
the Fas receptor. While E5 did not down-regulate TRAIL receptor expression, it was
found to inhibit TRAIL signaling by interfering with the formation of the TRAIL DISC
and thereby inhibiting the cleavage of pro-caspases 8 and 3, as well as PARP.

Papillomaviruses and Malignant Transformation
HP Vs are small, nonenveloped, double-stranded DNA viruses whose natural
cellular hosts are keratinocytes. Infection with HPV occurs below the surface of the
epithelium in the basal layer, and the life cycle of the virus is closely connected with the
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differentiation program of the cells it infects.

The most common phenotypical

manifestations of HPV infection are warts and papillomas of the skin, and various genital
hyperplastic epithelial lesions.

Over 100 HPV genotypes have been identified and

approximately 33% of these genotypes are associated with lesions of the genital tract.
HPVs that infect the genital tract can be subdivided into two categories: low-risk and
high-risk. Low-risk (LR)-HPVs such as types 6 and 11 generally cause benign warts
which rarely progress to cancer. On the other hand, high-risk (HR)-HPVs such as types
16, 18, 31 and 45 are associated with the development of high-grade lesions which can
progress to cancer.
All HPVs have a common genomic organization and encode 8 proteins: El, E2,
E4, E5, E6, and E7 (early) and LI and L2 (late). El and E2 are replication factors and
are also involved in transcription control; E4 and E5 are believed to regulate late viral
functions although their role is not clearly understood; E6 and E7 are oncoproteins; and.
LI and L2 are structural proteins (Longworth & Laimins, 2004).
oncoproteins

The E6 and E7

of the high-risk strains are the main contributors to malignant

transformation (Finzer et al., 2002, Munger, 2002). It is believed that a combination of
persistent infection by high-risk strains along with their inadequate clearance are the main
factors contributing to the integration of HPV genomes into the DNA of the host - a
critical step in tumorigenesis.

As a result of integration, the E2 open reading frame

(ORE) is disrupted, leading to a loss of E2 expression and its repressive action on E6 and
E7, as well as a concomitant rise in the levels of these oncoproteins.
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Modulation of Apoptosis by E6
The E6 oncoprotein has been widely studied because of its potent tumorigenic
properties. E6 is a relatively small protein (150 amino acids) and is produced in two
forms: a full-length version of ~ 16 kDa and a smaller version of about half that size
corresponding to the N-terminal half of the full-length protein (Mantovani & Banks,
2001). One of the primary targets of E6 is the tumor suppressor p53 (Scheffner et al.,
1990, Wemess et al., 1990).

In the early stages of HR-HPV infection, E7 induces a

significant increase in cell proliferation as a result of its interaction with retinoblastoma
(RB), which triggers the expression of p53 (Longworth & Laimins, 2004). Under normal
physiological conditions, this rise in p53 levels would lead to cell cycle arrest and/or
apoptosis, depending on the intensity of the damage or stimulus.

However, in this

situation, E6 binds to p53 with the aid of E6-associated protein ligase (E6-AP) and
prevents p53 from inducing growth arrest and apoptosis by targeting it for degradation
through the ubiquitin-proteasome pathway (Huibregtse et al., 1991). E6 also precludes
the growth-suppressive activities of p53 by cytoplasmic sequestration and by
transcriptional suppression of its target genes (Mantovani & Banks, 2001).
A number of proteins other than p53 are targeted by E6. These include proteins
involved in the regulation of transcription and DNA replication such as p300/CBP (Patel
et al., 1999, Zimmermann et al., 1999), IRF-3 (Ronco et al., 1998), liMcm? (Kuhne &
Banks, 1998, Kukimoto et al., 1998), E6TP1 (Gao et al., 1999) and ADA3 (Gao et al..
1999, Zeng et al., 2002); proteins involved in apoptosis and immune evasion such as Bak
(Thomas & Banks, 1998), c-Myc (Gross-Mesilaty et al., 1998), TNF receptor 1 (TNFRl) (Filippova et al., 2002) and FADD (Filippova et al., 2004); proteins involved with
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epithelial organization and differentiation such as paxillin (Tong & Howley, 1997),
E6BP/ERC-55 (Chen et al., 1995), zyxin (Degenhardt & Silverstein, 2001), and fibulin-1
(Du et al., 2002); proteins involved in cell-cell adhesion, polarity, and proliferation
control that contain a PDZ-binding motif such as liDLG (Kiyono et al., 1997, Lee et al.,
1997), hScrib (Nakagawa & Huibregtse, 2000), MAGI-1 (Glaunsinger et al., 2000,
Thomas et al., 2001), MAGI-2, MAGI-3 (Thomas et al., 2002), and MUPPI (Lee et al.,
2000); and proteins involved in DNA repair such as XRCCI and 6-0-methylguanineDNA methyl transferase (Srivenugopal & Ali-Osman, 2002).
Two of these proteins, Bak and myc, were the first apoptosis-related targets of E6
to be identified. Thomas & Banks found that E6 inhibits Bak-mediated apotosis by direct
binding to Bak, an interaction that is conserved from HR- to LR-HPVs (Thomas &
Banks, 1998, Thomas & Banks, 1999). In laryngeal cells, E6 was found to inhibit TNFmediated apoptosis by reducing the expression of Bak without significantly affecting the
expression of caspase-3 and -8 (Du et al., 2004).

Like p53, both Bak and myc are

ubiquinated by E6AP and degraded in the ubiquitin-proteosome pathway (Gross-Mesilaty
et al., 1998, Thomas & Banks, 1998).
Over the past several years, our laboratory has discovered novel E6 binding
partners that have helped to elucidate the role of E6 in immune evasion. We have shown
that

E6

can

inhibit

TNF-mediated

apoptosis

in

mouse

fibroblasts,

human

monocytes/histocytes and osteosarcoma cells by binding to the death domain of the TNFRl

and preventing it from interacting with TRADD (Filippova et al., 2002).

Paradoxically, stable transfection of E6 in human cells does not always result in
protection from TNF-mediated apoptosis. We found that clones with a high level of E6
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expression were more sensitive to apoptosis induced by TNF than clones with a low level
of E6 expression (Filippova et al., 2005). This finding is consistent with literature reports
which describe both the ‘sensitization’ (Liu et al., 1999, Vikhanskaya et al., 2002) and
‘protection’ properties of E6 (Duerksen-Hughes et al., 1999).

With regard to Fas-

mediated apoptosis, we have shown that E6 binds to FADD and mediates its degradation
via the ubiquitin proteosome pathway (Filippova et al., 2004).

Recently, we

demonstrated that E6 can also protect human cells (HCT116) from TRAIL-induced
apoptosis by accelerating the degradation of FADD and caspase-8 (Garnett et al., 2006).
In these studies, the targeting of TNF-R1, FADD and caspase-8 by E6 resulted in the
suppression of caspase activation and protection from apoptosis (Figure 1). However,
our unpublished observations that E6 does not interact with TRADD or Fas suggests that
the binding of E6 to TNF-R1, FADD and caspase-8 is specific. Interestingly, we also
found that E6 does not interfere with the mitochondrial apoptotic pathway.

Thus,

through the activities of E6, HR-HPVs can interfere with both p53-dependent and independent apoptotic pathways in order to create a cellular environment that facilitates
viral propagation.
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Figure 1. HPV 16 E6 exploits similarities in the apoptotic signaling pathways of TNF,
FasL and TRAIL. E6 inhibits TNF- and Fas-mediated apoptosis by binding to TNF R1
and to FADD. E6 protects cells from TRAIL-mediated apoptosis by accelerating the
degradation of FADD and caspase-8.
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Host Defense Mechanisms against HPV Infection
HPVs are persistent viruses that can remain in their hosts for long periods of time
before causing any ill effects. Generally, the host reacts to viral pathogens by generating
both humoral and cell-mediated responses. Humoral responses are typically antibodymediated and involve the secretion of antibodies such as immunoglobulin A (IgA) and
immunoglobulin G (IgG). Cell-mediated responses, on the other hand, are carried out by
immune effector cells such as dendritic cells (DCs), NK cells, macrophages and T
lymphocytes which secrete a number of cytokines including INF and TNF, and upregulate the expression of FasL and TRAIL on their cell surface.
In the case of HPV infection, the immune response is frequently weak or
undetectable, and accompanied by little or no inflammation.

Several recent studies

confirm the intractability of HPV both to detection and clearance by the host. For
example, Welters et al. found that none of the HPV 18 positive patients with genital
cancer displayed reactivity of type 1 T-helper (Thl) cells to HPV 18 E6 (Welters et al.,
2006). This finding confirmed their previous report regarding the lack of E6-specifIc Thl
immunity in patients with lesions induced by HPV 16 (de Jong et al., 2004).
Even when an immune response is elicited, it may not be able to clear the virus.
For example, Bard and coworkers examined the role of innate humoral immunity in
response to FIPV infection of the cervix. They found that infection of the cervix with
HR-HPVs led to a substantial increase in the levels of lysozyme and lactoferrin as well as
IgG, total-IgA and secretory-IgA (S-IgA) (Bard et al., 2004). However, the increased
concentration of these proteins was not able to prevent the spread of HPV infection, and
the lower S-IgA/total-IgA ratio in HPV positive patients compared to the control group
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suggested that HPV could evade detection by altering the local humoral immune response
(Bard et al., 2004). These findings are consistent with a pair of reports by de Gruijl et al.
and Bontkes et al., respectively, in which they examined cell-mediated and humoral
responses to HPV 16 vims-like particles (VLPs). In the first report, de Gmijl et al.
showed that Thl responses (measured by IL-2 release) and IgG responses to the major
capsid protein LI of HPV 16 were more robust in patients with abnormal cervical
cytology than in HPV negative patients, and that in the former these responses were
associated with persistence and the progression of premalignant lesions to high grade
lesions (de Gruijl et al., 1999).

The authors concluded that the observed Thl/lgG

responses were insufficient to mitigate viral propagation and disease progression. In part
2 of their study, Bontkes et al. examined the relationship between local and systemic IgA
and IgG responses to HPV VLPs and found that systemic, but not local IgA responses
correlated with a positive clinical outcome (i.e., viral clearance and resolution of lesions)
(Bontkes et al., 1999).
Although HR-HPVs are ‘clever’ at evading immune detection, studies such as the
latter suggest that the immune system can be successful at controlling HPV infection.
Indeed, a number of reports suggest that systemic Thl responses against HPV proteins
are associated with health. For example, it was shown that healthy patients demonstrated
Thl reactivity to both HPV 16 and 18 E6 (Welters et al., 2003, Welters et al., 2006). In a
separate study, a consistent Thl pattern was observed in a group of formerly HPV
positive women whose HPV infection was subsequently cleared (Scott et al., 1999).
Interestingly, the Thl pattern observed in these women actually preceded viral clearance
(Scott et al., 1999). Elevated levels of T lymphocytes (particularly CD4+ cells) and
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macrophages have also been found in patients with regressing genital warts (Coleman et
al., 1994). Studies of immunodefficient patients provide further insight into the response
of the immune system to HPV infection. In their study, Ellerbrock et al. reported that
20% of human immunodeficiency virus-infected patients, with no prior history of
cervical cancer, developed squamous intraepithelial lesions (SIL) of the cervix within 3
years of the start date of a prospective study (Ellerbrock et al., 2000). Recently, it was
reported that men infected with HIV had higher levels of HPV DNA in their urine than
HIV negative men, and 81.4% of the HPV types represented by the DNA in the urine of
the HIV positive men were from HR strains (Smits et al., 2005). These studies suggest
that the immune system is successful at preventing many cases of HPV infection from
progressing to malignancy and may explain instances of spontaneous regression of warts
observed in some patients.
Langerhans cells (LC), a type of DC that monitors squamous mucosal surfaces,
are an integral part of the immune system’s arsenal. These cells are likely the first
immune cells to encounter HPV in premalignant lesions such as SILs. Work by several
groups suggests that function of LCs may be impaired because of their low density and
stunted dendritic processes within SILs (al-Saleh et al., 1995, Viac et al., 1993).
However, using an organotypic culture model to approximate the microenvironment of a
SIL, Hurbert et al. demonstrated that LCs were fully capable of inducing apoptosis in
HPV positive keratinocytes and that the interaction of LCs with HPV positive cells did
not result in their demise (Hubert et al., 2001). Therefore, the ability of HPV to establish
chronic infection is likely not the result of an inadequate host-immune response, but to
the ability of the virus to evade host-immune surveillance mechanisms.

19

Therapeutic Approaches to Cervical Cancer
HR-HPVs, such as HPV 16 and HPV 18, play a pivotal role in the
pathophysiology of cervical cancer (Longworth & Laimins, 2004, Mantovani & Banks,
2001) which accounts for one-fifth of all cancer-related deaths among women, and is the
second most common cancer worldwide (Parkin et al., 2001, Pisani et ah, 2002). While
surgery, radiation and chemotherapy are commonly used to treat cervical cancer, vaccine
therapies will also be available in the near future. Two vaccines, one being developed by
Merck and the other by GlaxoSmithKline (GSK), hold great promise for the eradication
of this deadly disease (Cohen, 2005). Both vaccines take advantage of the ability of the
HPV LI capsid protein to self assemble into VLPs when expressed in cells. So far,
studies suggest that these LI VLP vaccines are safe and highly immunogenic. Indeed,
the Merck and GSK vaccines have performed exceptionally well in clinical trials with
nearly 100 percent of recipients experiencing protection against HPV 16 and 18. Because
these vaccines are prophylactic, it is unlikely that they will have the same efficacy against
existing infections or lesions. For this reason the therapeutic vaccine approach is being
pursued by a number of investigators.

Recently, scientists from ImmunoVaccine

Technologies and several academic labs reported that the peptide-based therapeutic
vaccine, VacciMax, which contains an E7 H2-D

CTL epitope as the primary

immunogen, could eliminate established FIPV 16-expressing tumors in mice (Daftarian et
al., 2006). This is only one of several therapeutic vaccine approaches currently being
explored by scientist. Others include viral-vector, bacterial, nucleic acid and dendritic
cell vaccines (Roden et al., 2004).
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Despite the success of therapeutic and prophylactic vaccines in preclinical and
clinical trials, these approaches are not without limitations. For example, safety, labor
intensive procedures, and inhibited repeat immunization are common drawbacks of
therapeutic vaccines (Roden et al., 2004).

As for prophylactic vaccines, the main

uncertainties include 1) long-term safety, 2) loss of HPV type-specificity, and 3) costeffectiveness, especially in developing countries where the majority of cervical cancers
occur (Lowy & Schiller, 2006).
While a considerable amount of research has been done on the role of HR-HPVs
in the etiology of cervical cancer, many of the actions of these viruses that promote
persistence and immune evasion have not been fully elucidated. A full understanding of
the events that occur during the time HR-HPVs establish a successful infection may
reveal novel molecular therapeutic targets, and lead to the development of therapies
designed to target known culprits such as E6. These approaches should be considered as
complimentary to existing vaccine-based therapies, which are not likely to protect against
all HR-HPV infections. Additionally, they increase the portfolio of therapeutic options
so that an effective response will be available when necessary.

Purpose of this Study
The ability of E6 to abrogate TNF- and Fas-mediated apoptosis suggests that E6
may also impair cellular responses to TRAIL as do other viral proteins such as HPV 16
E5 and HIV tat. A likely reason for this is that E6 mediates the degradation of FADD
and caspase-8, and these proteins are thought to function as key components of the
TRAIL DISC in most cell types. To examine the influence of E6 on TRAIL-mediated
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apoptosis, the following questions were examined:

1) Does E6 protect cells from

TRAIL-mediated apoptosis? (chapters 2 & 3) 2) In cases where E6 inhibits TRAIL
signaling, what is the mechanism underlying this protection? (chapter 2) 3) Does the
ability of E6 to protect some, but not all cells from TRAIL reflect cell type-specific
differences in the TRAIL signaling pathway? (chapter 3)
As noted, one of the primary strategies employed by HP Vs to escape
immunological surveillance during the progression to cervical cancer is to interfere with
host-mediated apoptosis. In this respect, E6 seems to function as a key player. The
ability of E6 to block TRAIL-induced apoptosis would imply that molecules capable of
canceling its protective effect can be developed for potential therapeutic applications.
Moreover, an understanding of this phenomenon may help to target TRAIL-based
therapies to cases where they are most likely to benefit the patient. However, the ability
E6 to protect some cell types from TRAIL-mediated apoptosis but not others would
suggest that we have the opportunity to further elucidate molecular mechanisms of the
TRAIL apoptotic pathway which are not completely understood. This study therefore
contributes to our understanding of virus/host interactions, particularly the strategies used
by viruses to undennine host defenses, and thus will enhance our ability to design novel
and effective therapeutic strategies to combat cervical cancer. Furthermore, the potential
discovery of an alternative cell death pathway for TRAIL may open up the possibility of
a new set of prospective targets for therapeutic intervention.
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CHAPTER TWO
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Abstract

Viruses have developed sophisticated strategies to evade host defenses and
facilitate the production and spread of progeny, hi this study, we show that transfection
of the human papillomavirus (HPV) 16 E6 oncogene into HCT116 cells provides
protection from TRAIL-mediated apoptosis.

Additionally, we demonstrate that the

protection provided by E6 is dose-dependent because higher levels of E6 provide greater
protection. The mechanism underlying this protection involves a rapid reduction in the
protein levels of both FADD and pro-caspase 8, which results in suppression of the
activation of caspases 8, 3 and 2.

Interestingly, E6 does not interfere with the

mitochondrial apoptotic pathway even though HCT116 cells have been classified as type
II cells with regard to TRAIL signaling. These findings demonstrate that E6 has a more
generalized effect on signaling by death ligands than was previously thought and support
the notion that E6 can utilize p53-independent mechanisms to modulate cell survival.

Keywords: TRAIL, HPV 16, E6, apoptosis, caspase activation
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Introduction

The cytotoxic ligand Apo2L/TRAIL (TNT-related apoptosis inducing ligand) is a
member of the tumor necrosis factor (INF) ligand family that has gained notoriety for its
ability to selectively kill most cancer cells while sparing the majority of normal cells (1,
2). TRAIL-induced apoptosis is initiated by the binding of TRAIL to death receptor
(DR)4 (3) and/or DR5 (4, 5). TRAIL forms a homotrimer and associates with three
receptors (6). Homotypic, protein-protein interactions between conserved death domains
and death effector domains lead to the assembly of Fas associated death domain (FADD)
and pro-caspase(s) 8/10 molecules at the C-terminus of the receptors to form the death
inducing signaling complex (DISC) (7, 8). Activation of caspase(s) 8/10 at the DISC is
then followed by the activation of executioner caspases, such as caspases 3 and 7, the
cleavage of cellular substrates, and the loss of cell viability.
In addition to its potent anticancer properties, a growing body of evidence
suggests that TRAIL may play an important role in host defense against viral infection.
Notably, TRAIL is expressed on a variety of cells involved in host defense against viral
infection including cytotoxic T cells (9, 10), dendritic cells (11), monocytes/macrophages
(12), and natural killer (NK) cells (13, 14).
Not surprisingly, viruses have developed sophisticated strategies to both exploit
TRAIL’S potent cytotoxic properties, and to modulate cellular responses to TRAIL. For
example, infection with human immunodeficiency virus-1 (HIV-1) can trigger the
expression of TRAIL in monocytes, contributing to HIV-1 pathogenesis by inducing
CD4(+) T cell death (15). Alternatively, vimses may block death receptor signaling by
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interfering with one or more components of the signaling pathway. Exogenous HIV-1 tat
has been shown to protect cells from TRAIL-mediated apoptosis (16, 17), as has the
adenovirus E3-6.7K/10.4K/14.5K complex (18) and the human papillomavirus (HPV) 16
E5 protein (19). All of these viral proteins inhibit TRAIL-induced cell death by targeting
the TRAIL signaling cascade.
The E6 oncoprotein of high-risk HP Vs, such as HPV 16, plays a pivotal role in
the pathophysiology of cervical cancer (reviewed in 20, 21), which accounts for a large
number of deaths among women worldwide (22, 23). One of the primary targets of E6 is
the tumor suppressor p53 (24, 25). It is well-known that E6 binds to p53 and mediates its
degradation. However, E6 binds to a number of cellular targets other than p53, including
proteins involved in apoptosis such as Bak (26) and c-Myc (27). Furthermore, work by
our lab has implicated E6 in the evasion of host-mediated apoptosis. We have shown that
E6 protects cells from TNF-induced apoptosis by binding to the death domain (DD) of
TNF R1 and preventing it from interacting with TNF R1-associated death domain
(TRADD) (28). In the case of Fas-mediated apoptosis, E6 inhibits signaling from Fas by
binding to FADD and targeting it for degradation via the ubiquitin-proteasome pathway
(29).
The ability of E6 to abrogate TNF- and Fas-mediated apoptosis raised our interest
in the possibility that E6 could also influence signaling by TRAIL because TNF, Fas and
TRAIL utilize common mechanisms of signaling.

There is evidence, however, that

despite the similarities in the signaling pathways of these ligands, some cells that express
E6 (e.g., SiHa) are resistant to TRAIL while others (e.g., CasKi) are sensitive (30). The
SiHa and CasKi cell lines contain 1 to 2 and ~600 copies of integrated HPV 16 per cell
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(31), respectively, and also express other HPV proteins, such as E5, which may influence
cellular responses to TRAIL (19).
In this study, we investigated whether HPV 16 E6 modulates cellular responses to
TRAIL. Since TRAIL-mediated apoptosis is not abrogated in all E6-expressing cells, we
examined the influence of E6 alone (i.e., in the absence of other HPV proteins) on
apoptotic signaling by TRAIL in a human epithelial, keratin-producing cell line
(HCT116). We found that TRAIL-induced apoptosis is impaired in HCT116 cells stably
expressing E6 by a mechanism involving the rapid degradation of both FADD and procaspase 8. Our findings provide additional evidence that E6 can modulate death receptor
signaling by exploiting similarities in their signaling pathways.
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Results

Transfection of HPV 16 E6 into HCT116 Cells Provides Protection from TRAILmediated Cell Death

To investigate the possibility that E6 modulates cellular responses to TRAIL, we
stably transfected HPV 16 E6, in the sense or antisense orientation, into HCT116 cells, an
epithelial cell line that expresses keratin. To determine whether these cells were sensitive
to TRAIL, we treated a pool of cells stably transfected with the antisense version of
epitope-tagged HA-E6 (HCT116E6ASP) with 5, 25 and 50 ng/ml of TRAIL in the
presence or absence of the protein synthesis inhibitor cycloheximide. Cycloheximide
was used in combination with TRAIL to potentiate its cytotoxicity because, like TNF,
TRAIL can trigger a protective pathway in some cell types via the activation of NF-kB,
whose targets include genes encoding intracellular inhibitors of apoptosis such as XIAP
and c-FLIP (32). Treatment of HCT116E6ASP cells with TRAIL led to a decrease in cell
viability in both the absence (24%) and presence (74%) of cycloheximide, providing
evidence both that these cells are sensitive to TRAIL and that sensitization is potentiated
by cycloheximide (Figure 2A).

Hence, cycloheximide (see Methods for specific

concentrations) was used in subsequent experiments to enhance cell killing by TRAIL.
To determine the effect of E6 on apoptotic signaling by TRAIL, stable pools expressing
the sense or antisense versions of HA-E6 (HCT116E6SP and HCT116E6ASP,
respectively) were treated with 25 ng/ml and 50 ng/ml TRAIL. Interestingly, the sense
pool was somewhat more resistant to TRAIL-mediated cell death than the antisense pool
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Figure 2. Transfection of E6 into HCT116 cells provides protection from TRAILinduced apoptosis. HCT116 were transfected with either HA-E6S or HA-E6AS to create
stable pools and clones. Parental cells as well as HA-E6S and HA-E6AS pools and
clones were incubated with the indicated concentrations of TRAIL for 16 h in the
presence of cycloheximide (CHX). After 16 h, cell survival was measured by the MTT
assay. Results of three independent experiments are shown, and the error bars represent
the standard deviation. (A) The response of HCT116E6ASP (HA-E6AS pool) to 5, 25
and 50 ng/ml TRAIL alone or in the presence of cycloheximide. (B) The response of
HCT116E6ASP and HCT116E6SP (HA-E6S pool) to cycloheximide plus 25 and 50
ng/ml TRAIL. *, P < 0.05 versus HCT116E6ASP cells treated with 50 ng/ml TRAIL.
(C) Cell viability after treatment with 25 ng/ml TRAIL in the presence of cycloheximide,
as well as HA-E6 levels, were determined for HCT116 (Lane 1), HCT116E6S1 (Lane 2),
HCT116E6S7 (Lane 3) and HCT116E6S29 (Lane 4) cells by the MTT assay and
immunoprecipitation, respectively,
The white bars represent treatment with
cycloheximide alone and the black bars represent treatment with cycloheximide and
TRAIL (25 ng/ml). Immunoprecipitation of HA-E6 with anti-HA antibodies was
perfonned on cell lysates from untreated cells. **, P < 0.01;
, P < 0.001 versus
untransfected E1CT116 cells treated with 25 ng/ml TRAIL. (D) Cell viability of
HCT116E6ASP and HCT116E6S29 cells following treatment with 50 ng/ml TRAIL plus
cycloheximide for 0, 2, 4, 8, and 16 h.
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(Figure 2B). To further investigate this finding, individual clones from the sense pool
were first selected and expanded, and then subjected to treatment with TRAIL. We found
that clones expressing detectable levels of HA-E6S protein (HCT116E6S1 and S29) were
significantly more resistant to TRAIL than clones in which HA-E6S expression could not
be detected (e.g., S7), or untransfected parental cells (Figure 2C).

For example,

following exposure to 25 ng/ml TRAIL the percent viability of HCT116E6S1 and
HCT116E6S29 cells was 66% and 81%, respectively, compared to 29% for
HCT116E6S7, and 43% for the parental cells (Figure 2C). Since treatment with TRAIL
was performed over a 16 h time span, we were also interested in determining how E6
affected cell viability at different time points during the treatment period. Therefore, we
assessed the response of FICT116E6ASP and HCT116E6S29 cells to TRAIL (50 ng/ml)
at 0, 2, 4, 8 and 16 h. We observed a time-dependent decrease in the viability of both
HCT116E6ASP and HCT116E6S29 cells following exposure to TRAIL (Figure 2D).
However, HCT116E6S29 cells were significantly more resistant to TRAIL than were the
HCT116E6ASP cells at 4, 8 and 16 h.
We then examined the morphological features of TRAIL-induced cell death in
cells expressing the sense or antisense versions of HA-E6. This was accomplished by
comparing the nuclei of these cells after 0 and 6 h of treatment with TRAIL, followed by
fixing and staining with DAPI. Cells were considered non-viable (apoptotic) if they
exhibited a loss of nuclear shape and/or nuclear fragmentation. Visualization of DAPI
stained nuclei by fluorescence microscopy revealed considerable fragmentation of nuclei
(20.5%) from HA-E6AS expressing cells at 6 h compared to much lower levels of
nuclear fragmentation (7.9%) from E6-expressing cells (Figure 3). Together, these
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Figure 3. Morphology of E6-expressing HCT116 cells in response to TRAIL is
consistent with protection from apoptosis. HCT116 cells expressing either the antisense
(HCT116E6ASP) or sense (FICT116E6S29) version of E6 were seeded on coverslips in
6-well plates and treated with TRAIL (50 ng/ml) plus cycloheximide for 0 or 6 h. After
fixation in 4% paraformaldehyde, the slips were mounted using Vectashield mounting
media with DAPI. Morphology of cells was analyzed by phase-contrast microscopy, and
the DAPI-stained nuclei monitored using a UFA 1 FI objective. The cells in each panel
were magnified 1000 times with the oil immersion lens. For each set of three panels, the
left represents phase contrast microscopy, the middle the DAPI staining pattern, and the
right a merged image. The green background in the merged image is due to the light used
to obtain a visible image.
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findings clearly demonstrate that E6 can protect HCT116 cells from TRAIL-induced cell
death.

TRAIL-induced Cell Death in HCT116 Cells Occurs by Apoptosis and is Caspasedependent

The morphological analysis described above is consistent with an apoptotic form
of cell death.

To confirm that TRAIL triggers apoptosis in HCT116 cells under our

conditions, the cells were treated with TRAIL for 3, 6, 9, 12 and 16 h and the lysates
were analyzed for PART cleavage by immunoblot.

PARR is a well-known substrate of

the executioner caspases 3 and 7 and its cleavage pattern is a widely used marker of
apoptotic cell death (33). As expected, we found that full-length PARP (116 kDa) was
cleaved into an 89 kDa protein 6 to 9 h following treatment with TRAIL, indicating that
cell death occurred by apoptosis (Figure 4A). To determine whether TRAIL-induced
apoptosis in HCT116 cells is caspase-dependent, the cells were treated with TRAIL or
with a combination of TRAIL and the pan caspase inhibitor Z-VAD-FMK. Z-VADFMK provided significant protection from TRAIL-mediated apoptosis, indicating that
cell death induced by TRAIL in HCT116 cells is caspase-dependent (Figure 4B). Both
findings are thus consistent with previous reports that TRAIL induces apoptosis via a
caspase-dependent mechanism in HCT116 cells (34, 35).
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Figure 4. Cell death triggered by TRAIL in HCT116 cells occurs by apoptosis and is
caspase-dependent. (A) HCT116 cells were treated with TRAIL (50 ng/ml) in
combination with cycloheximide at the indicated time points and then lysed. Afterward,
the lysates were analyzed for PARP cleavage by immunoblot. (B) HCT116 cells were
treated with cycloheximide alone or the indicated combinations of cycloheximide,
TRAIL (50 ng/ml) and Z-VAD-FMK (50 pM) for 16 h. After 16 h, the percentage of
viable cells was determined by the MTT assay. For B, results of three independent
experiments are shown, and the error bars represent the standard deviation. **, P < 0.01
versus HCT116 cells treated with cycloheximide and TRAIL alone.
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E6 Protects HCT116 Cells from TRAIL-induced Apoptosis in a Dose-dependent Manner

To more carefully examine the relationship between E6 expression and sensitivity
to TRAIL, we created a cell line derived from HCT116 cells in which we could modulate
the levels of HA-E6 based on the concentration of doxycycline in the media. Creation of
the HCT116 E6-inducible cell line required two stable transfections.

The first

transfection was performed with a tetracycline/doxycycline controlled transactivator
(pTet-Off), and stable clones were selected and screened by transient transfection with a
plasmid containing firefly luciferase under the control of the tetracycline/doxycycline
response element (pTRE-luc). Of the stable clones isolated, clone #3 (HCT116tet3) was
found to have the lowest background expression of luciferase as well as the greatest
induction of the reporter gene following doxycycline treatment (Figure 5A). Based on
this finding, the HCT116tet3 clone was selected for further experimentation and was then
transfected with pTRE-HA-E6S. Following the selection and expansion of individual
clones, clones expressing HA-E6, as detennined by immunoprecipitation/immunoblot,
were selected. To confirm that HA-E6 gene expression could be modulated, messenger
RNA from one of these clones, HCT116tet3E6S22, was subjected to RT-PCR analysis
after incubation of HCT116tet3E6S22 cells in different concentrations of doxycycline.
As expected, HA-E6 mRNA levels were modulated by doxycycline in the Tet~Off cell
line (Figure 5B). We then treated HCT116tetE6S22 cells with TRAIL in the presence of
different concentrations of doxycycline to determine the effect of varying the levels of
HA-E6 on cell viability. We found that in the presence of maximal levels of HA-E6 (no
doxycycline), the cells experienced significant protection from TRAIL as compared to
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Figure 5. Modulation of HA-E6 levels alters the sensitivity of HCT116 cells to TRAIL.
(A) Parental HCT116 cells were transiently co-transfected with pTet-Off and pTRE-luc
constructs (control) while HCT116tet3 cells (parental HCT116 cells stably expressing the
pTet-Off plasmid) were transiently transfected with pTRE-luc alone. The cells were then
treated or untreated with doxycycline (1000 pg/ml) and the level of luciferase expressed
was measured by a luminometer according to the manufacturer’s instructions. Results of
three independent experiments are shown, and the error bars represent the standard
deviation. (B) RT-PCR analysis of HA-E6 mRNA levels in HCT116tet3 cells {lane 5),
HCT116E6S29 cells (lane 6) and HCT116tet3E6S22 cells (lanes 1-4: 0, 5, 20 and 400
pg/ml doxycycline, respectively). Cofilin (CFL) levels were also measured and served as
a loading control. (C) Response of control cells (HCT116tet3—HCT116 cells stably
expressing the pTet-Off plasmid but not expressing E6) and HCT116tet3E6S22 cells
(expressing E6) to TRAIL (50 ng/mL). Cells were cultured in the indicated concentration
of doxycycline and then treated with TRAIL for 16 h in the presence of cycloheximide.
After 16 h, the percentage of viable cells was determined by the MTT assay. Results of
three independent experiments are shown, and the error bars represent the standard
deviation. *, P < 0.05; **, P < 0.01 versus HCT116tet3 cells treated with the
corresponding concentrations of doxycycline.
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cells lacking E6 (HCT116tet3) (Figure 5C). Following the down-regulation of HA-E6 by
increasing the amount of doxycycline added to the media, HCT116tetE6S22 cells became
more sensitive to TRAIL (Figure 5C). These findings demonstrate that E6 can modulate
TRAlL-mediated apoptosis in a dose-dependent fashion.

E6 Acts Upstream of the Mitochondrial Apoptotic Pathway in HCT116 cells

The TRAIL cell death pathway is believed to follow a model similar to the type
I/type II system described for Fas (34). According to this model, DISC fonnation in type
I cells is robust and caspase 8 directly cleaves caspase 3. However, in type II cells, DISC
formation is weak, and caspase 8 cleaves Bid leading to the amplification of apoptotic
signals from TRAIL via the mitochondrial pathway.

El-Deiry and coworkers have

suggested that HCT116 cells behave like type II cells (34). Thus, it was of interest to
detennine whether the inhibitory effect of E6 on apoptotic signal transduction by TRAIL,
and the resulting survival of HCT116 cells, was due to its influence on the mitochondrial
apoptotic pathway.
To activate the mitochondrial pathway, E6-expressing (HCT116E6S1 and
HCT116E6S29) and control (HCT116E6ASP) cells were treated with different
concentrations of the DNA damaging agent mitomycin C or with ceramide for 24 h.
Following the treatment period, the percentage of surviving cells was detennined by the
MTT assay.

We found no difference in the sensitivity of E6-expressing and control

HCT116 cells to either mitomycin C or ceramide (Figure 6A and B). We also examined
the levels of Apaf-1 (apoptosis protease activating factor 1) in cells expressing or not
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Figure 6. E6-mediated resistance of HCT116 cells to TRAIL occurs upstream of the
mitochondrial apoptotic pathway. HCT116 cells stably expressing HA-E6AS and HAE6S were treated with the indicated concentrations of mitomycin C (A) and ceramide (B)
for 24 h. After 24 h, cell survival was measured by the MTT assay. Results of three
independent experiments are shown, and the error bars represent the standard deviation.
(C) HCT116E6ASP and HCT116E6S29 cells were analyzed for Apaf-1 (-130 kDa) and
p53 levels by immunoblot following treatment with mitomycin C (2 pg/ml) for the
indicated hours, p-actin served as a loading control.
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expressing HA-E6S at 0, 12, 24 and 36 h after incubation with a low dose of mitomycin
C (2 pg/ml). Apaf-1 (-130 kDa) is a key component of the apoptosome which is formed
shortly after mitochondrial depolarization. In the apoptosome, Apaf-1 associates with
cytochrome c and pro-caspase 9 leading to the activation of caspase 9 and downstream
executioner caspases. We observed an elevation in Apaf-1 levels at 12 h in both HAE6S-expressing and non-expressing cells followed by a gradual decrease to basal levels at
24 and 36 h (Figure 6C). We then re-probed the membrane with anti-p53 antibodies to
assess p53 levels in the two cell lines and found higher basal and induced levels of p53 in
the HCT116E6ASP cells than in the HCT116E6S29 cells (Figure 6C), consistent with the
known function of E6 in targeting p53 for degradation.
In light of these findings we concluded that while the expression of E6 in type II
HCT116 cells causes resistance to TRAIL-mediated apoptosis (Figure 2B and C; Figure
3), cell death induced by known activators of the mitochondrial apoptotic pathway is not
blocked in these cells. Therefore, these data suggest that E6 inhibits TRAIL-mediated
apoptosis upstream of the mitochondrial apoptotic pathway, but do not entirely rule out
an effect on the mitochondria.

FADD is Necessary for TRAIL-mediated Apoptosis in HCT116 Cells and is Rapidly
Degraded in Cells Stably Expressing E6

The binding of TRAIL to DR4 and DR5 results in the formation of the TRAIL
DISC, which contains key signaling molecules required for transmitting apoptotic signals
from TRAIL to executioner caspases that carry out the cell death program (32). It is well
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established that both FADD and pro-caspase 8 are recruited to the TRAIL DISC and are
necessary for TRAIL-induced apoptosis in most cell types (7, 8).

To assess the

importance of FADD in the TRAIL cell death pathway in HCT116 cells, we first
determined whether FADD expression could be suppressed by post-transcriptional gene
silencing using siRNA directed against FADD. Because endogenous levels of FADD in
HCT116 cells are low, FADD protein analysis in this and subsequent experiments was
perfonned with transfected FADD (pcDNA3-FADD).

First, HCT116 cells were

transiently transfected with either non-specific siRNA (siControl) or siRNA targeting
FADD (siFADD), followed by pcDNA3-FADD 24 h later. To measure the transfection
efficiency of pcDNA3-FADD under these conditions, the cells were also co-transfected
with a plasmid coding for green fluorescence protein (GFP) (pE-lCMV-GFP).
Subsequently, the cells were lysed and level of FADD and GFP in the lysates was
analyzed by immunoblot. As expected, siFADD but not siControl significantly inhibited
FADD expression (Figure 7A). We once again transiently transfected HCT116 cells with
siControl or siFADD. Following transfection, the cells were treated with TRAIL and
TNF. TNF was included in the experiment because FADD is also considered to be an
important component of the signaling pathways induced by this ligand, and thus TNF
served as a positive control.

The cells were then analyzed by the MTT assay to

determine the number of surviving cells. The results demonstrate that both TRAIL- and
TNF-mediated apoptosis was significantly impaired by siFADD (Figure 7B), which
suggests that FADD plays an important role in apoptotic signaling by TRAIL in HCT116
cells.
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Figure 7. FADD is required for TRAIL-triggered apoptosis and its degradation is
accelerated in HCT116 cells harboring E6. (A and B) FADD is required for TRAILmediated apoptosis in HCT116 cells. (A) siRNA targeting FADD (siFADD) inhibits
FADD expression. Parental FICT116 cells were transfected with siControl and siFADD
as previously described. After 24 h, the cells were transfected with pcDNA3-FADD and
pE-lCMV-GFP and incubated for an additional 24 h. The cells were then lysed, and the
lysates were analyzed for the expression of FADD and GFP by immunoblot using antiFADD and anti-GFP antibodies. (B) Silencing FADD expression via RNA interference
protects HCT116 cells from TNF- and TRAIL-mediated apoptosis. Parental HCT116
cells were either transfected with non-specific, control siRNA (siControl) or siFADD and
incubated at 37°C for 24 h. Following incubation, the cells were treated with TNF (5
ng/ml) or TRAIL (50 ng/ml) in the presence of cycloheximide for 16 h. After 16 h, cell
survival was measured by the MTT assay. Results of three independent experiments are
shown, and the error bars represent the standard deviation. *, P < 0.05; **, P < 0.01
versus the corresponding siControl transfected cells. (C) FADD is rapidly degraded in
E6-expressing HCT116 cells. HCT116E6ASP and HCT116E6S29 were transfected with
pcDNA3-FADD and pE-lCMV-GFP for 24 h. After 24 h, cells were untreated or treated
with cycloheximide (CHX) at the indicated time points and then lysed. The levels of
FADD and GFP in the untreated and treated lysates were then analyzed by immunoblot
using anti-FADD and anti-GFP antibodies.
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To determine whether E6 impairs TRAIL-mediated apoptosis in HCT116 cells by
undennining the stability of FADD, we examined FADD protein levels in cells
expressing the sense or antisense versions of HA-E6. HCT116 cells expressing HA-E6S
(HCT116E6S29) and HA-E6AS (HCT116E6ASP) were treated with cycloheximide for
0, 2, 4, 8 and 16 h to suppress de novo protein synthesis and then lysed. Subsequently,
the lysates were subjected to immunoblot to examine any changes in the levels of FADD.
We observed a significant decrease in the levels of FADD (particularly at 8 and 16 h) in
the HCT116 HA-E6S29 cells compared to a very small decrease in the HCT116 HAE6ASP cells (Figure 7C).
Collectively, these findings suggest that E6 inhibits TRAlL-induced apoptosis in
HCT116 cells, at least in part, by mediating the rapid degradation of FADD. This is
entirely consistent with our previous observation that the impairment of Fas-mediated
apoptosis in E6-expressing U20S cells results from the targeted degradation of FADD
(29), and our results demonstrate that there is a substantial reduction in the levels of
transfected FADD in the presence of E6.

E6 Suppresses the Activation of Caspases 8, 3 and 2 in HCT116 cells by Accelerating the
Degradation of Pro-caspase 8

To further explore the mechanism by which E6 inhibits TRAlL-induced apoptosis
in HCT116 cells, we examined the effect of E6 on caspase activation in the extrinsic cell
death pathway.

HCT116 cells stably expressing HA-E6S (HCT116E6S29) and HA-

E6AS (HCT116E6ASP) were treated with TRAIL at intervals of 2 to 3 h and then lysed.
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Subsequently, the lysates were analyzed for caspase 8 and 3 activity using the appropriate
flourogenic substrates (see Materials and Methods) in the presence and absence of
inhibitors of each caspase. We also analyzed the activity of caspase 2 because it was
recently reported that this initiator caspase is involved in TRAIL-mediated apoptosis in
HCT116 cells (36). In cells expressing the HA-E6AS, caspase 8 activation occurred soon
after TRAIL treatment with a maximum level observed between 2 to 4 h, while caspase 3
activation began to increase at about 4 h and continued to rise at 6 h (Figure 8A).
However, in the cells expressing HA-E6S, the activation of caspases 8 and 3 was reduced
to less than half of peak levels. Interestingly, the activation of caspase 2 in the control
cells (HCT116E6ASP) was robust following TRAIL treatment, but was almost
completely inhibited in the cells expressing HA-E6S (Figure 8A).

These results are

consistent with our previous finding of E6-mediated FADD degradation, in that they
support the notion that E6 targets the TRAIL pathway upstream of the caspase cascade.
To determine whether E6 suppresses caspase activation by undermining the
stability of pro-caspase 8 and thus contributing to cellular resistance to TRAIL-mediated
apoptosis, we examined pro-caspase 8 protein levels in cells expressing either the sense
or antisense versions of HA-E6. As described above, HCT116 cells expressing HA-E6S
(HCT116E6S1

or

S29)

and

HA-E6AS

(HCT116E6ASP)

were

treated

with

cycloheximide for 0, 2, 4, 8 and 16 h to suppress de novo protein synthesis and then
lysed. Subsequently, the lysates were subjected to immunoblot to examine any changes
in the levels of pro-caspase 8. The levels of p-actin were also analysed and served as a
loading control. We observed a gradual, but significant decrease in the levels of procaspase 8 in the HCT116 HA-E6S cells compared to virtually no change in the
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Figure 8. The activation of caspases 8, 3 and 2 is attenuated in E6-expressing HCT116
cells due to the rapid degradation of pro-caspase 8. (A) The activation of caspases 8, 3
and 2 by TRAIL is suppressed in E6-expressing HCT116 cells. HCT116 cells stably
expressing HA-E6AS (HCT116E6ASP) and HA-E6S (HCT116E6S29) were treated with
TRAIL (50 ng/ml) in combination with cycloheximide for indicated time intervals and
then lysed. Afterward, the lysates were incubated with flourogenic substrates for capases
8 (Ac-IETD-pNA), 3 (Ac-DEVDAMC) and 2 (Ac-VDVAD-AMC) in the presence or
absence of the appropriate capase inhibitor (Ac-IETD-CHO, Ac-DEVD-CHO and AcVDVAD-CHO, respectively).
The released fluorochrome was measured with a
fluorimeter. Percent caspase activity was calculated by subtracting the activity in wells
containing inhibitor from the activity in wells lacking inhibitor and expressing this
number as a percentage of caspase activity in wells containing untreated HCT116E6ASP
cells.
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HCT116E6ASP cells (Figure 8B). The decrease in pro-caspase 8 levels was not due to
its activation because the cleaved forms of the proenzyme (p40/36 and p23) were not
detected.

Additionally, when HCT116E6ASP cells and HCT116E6S29 cells were

untreated or treated with cycloheximide for 4 h, and then subjected to the flourometric
caspase activity assay described above, there was no significant change in the activation
of caspase 8 in either cell line (Figure 8C). However, there was a large increase in the
activity of caspase 8 in HCT116E6ASP cells treated with cycloheximide and TRAIL,
which served as a positive control (Figure 8C).
We also examined the protein expression of pro-caspase 8 in HCT116E6ASP and
HCT116E6S29 cells under conditions where the cells were treated with TRAIL as well as
cycloheximide. In this experiment, cells were treated with TRAIL/cycloheximide for 0,
2, 4, 8 and 16 h, lysed and then subjected to immunoblot analysis with anti-caspase 8 and
anti-P-actin antibodies.

The expression of the p55/50 subunit of pro-caspase 8 was

higher in HCT116E6ASP cells than in HCT116E6S29 cells at 0 h (untreated). This is
consistent with the previous observation that pro-caspase 8 is rapidly degraded in the
presence of E6. From 2 to 16 h, there was a precipitous decline in the levels of the
p55/50 subunit in both cell lines accompanied by the appearance of the p43/41 cleavage
product (Figure 8D). This was expected since TRAIL treatment leads to the activation
and cleavage of pro-caspase 8. However, while the level of the p43/41 cleavage product
increased and then decreased in both HCT116E6ASP and HCT116E6S29 cells over time,
this change occurred earlier in the HCT116E6ASP cells than in the HCT116E6S29 cells
(Figure 8D). Therefore, we concluded that during the period of time when
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Figure 8. (B) The degradation of pro-caspase 8 is accelerated in E6-expressing HCT116
cells.
HCT116E6ASP and HCT116E6S29 cells were untreated or treated with
cycloheximide (CHX) at the indicated time points and then lysed. The levels of procaspase 8 and [3-actin were then analyzed by immunoblot using anti-capase 8 and anti-pactin antibodies. Monoclonal anti-caspase 8 antibodies (BD Pharmingen) recognize the
proform of human caspase 8, which migrates as a 50/55 kDa doublet, as well as the
cleaved forms (46/36 kDa and 23 kDa). (C) The reduction in pro-caspase 8 levels
following cycloheximide treatment is not due to its activation. The activation of caspase
8 in untreated or cycloheximide-treated HCT116E6ASP and HCT116E6S29 cells was
determined as described in (A). HCT116E6ASP cells treated with both cycloheximide
and TRAIL (50 ng/ml) served as a positive control. (D) The cleavage of pro-caspase 8 is
delayed in the presence of E6. HCT116E6ASP and HCT116E6S29 cells were treated
with TRAIL (50 ng/ml) and cycloheximide for 0, 2, 4, 8 and 16 h. The cells were then
lysed and the levels of pro-caspase 8 and P-actin were analyzed by immunoblot using
anti-capase 8 (Alexis Biochemicals) and anti-p-actin antibodies.
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HCT116E6S29 cells are resistant to TRAIL (Figure 2D) the cleavage of pro-caspase 8 is
delayed.
Together, these data provide substantive evidence that E6 protects HCT116 cells
from TRAIL by accelerating the degradation and delaying the cleavage of pro-caspase 8,
and demonstrate that E6 short-circuits the TRAIL signaling pathway in HCT116 cells by
targeting two of its essential components, FADD and pro-caspase 8.
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Discussion

Viruses have developed sophisticated ways to evade immune surveillance by the
host and to facilitate the production and spread of progeny (37). One of the primary ways
viruses avoid elimination is by protecting infected cells from host-mediated apoptosis.
Viruses employ several strategies to inhibit apoptosis of infected cells including
modulating ligand expression, inhibiting ligand-receptor interactions, interfering with the
DISC, suppressing caspase activation, and targeting the mitochondria (38). For example.
adenovirus EIB-19K, a Bcl-2 type protein, inhibits TNF-induced apoptosis by
suppressing mitochondrial activation (39, 40), while the E3-10.4/14.5/6.7 proteins inhibit
TRAIL-mediated apoptosis by decreasing the expression of DR4 and DR5 on the cell
surface (18). Bovine herpes virus-4 BORFE2 and equine herpes virus E8 prevent TNF
and Fas-induced apoptosis by interfering with caspase 8 (41, 42) while CMV abrogates
TNF, FasL and TRAIL-mediated apoptosis by suppressing the activation of caspase 8
(43).

Our results provide substantive evidence that HPV 16 E6 targets pro-caspase 8 in
order to

block the transmission of apoptotic

signals

from

TRAIL.

Co-

immunoprecipitation and mammalian two-hybrid experiments perfonned in our lab
demonstrate that pro-caspase 8 interacts with E6 and inhibiting the proteosome can
prevent its degradation in E6-expressing cells (manuscript in preparation). Since the
activation of caspase 8 initiates the caspase cascade, a reduction in the stability of procaspase 8 will affect sequential events in the pathway. Therefore, the suppression of
caspase 8, 3 and 2 activation in E6-expressing HCT116 cells appears to be a consequence
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of the ability of E6 to decrease the levels of pro-caspase 8 by targeting it for degradation.
These findings suggest that like FADD, pro-caspase 8 warrants recognition as a novel
target of E6. However, it should be noted that the interaction of E6 with FADD, and its
putative interaction with pro-caspase 8 does not imply that E6 lacks specificity because
we have been unable to demonstrate statistically significant binding between E6 and
TRADD (29) or between E6 and Fas (unpublished data).
Another novel finding of our study is that E6 inhibits TRAIL-induced activation
of caspase 2 in HCT116 cells. This finding is consistent with a recent report by Wagner
et al. showing that caspase 2 plays a role in TRAIL-induced apoptosis (36). In this
report, caspase 2 was found to act upstream of Bid cleavage and to be necessary for
TRAIL-mediated apoptosis in FICT116 cells but not HeLa cells. Our results also suggest
that caspase 2 activation occurs after the activation of caspase 8 but prior to the activation
of the mitochondrial pathway. A number of studies have found that caspase 3 can
directly activate caspase 2 (44, 45), which has led some investigators to conclude that
caspase 2 can function downstream of the mitochondria. On the contrary, other studies
have implicated caspase 2 in the activation of the mitochondrial pathway, either directly
or indirectly by facilitating the cleavage of Bid (46-48). In our study, E6 did not interfere
with the mitochondrial apoptotic pathway in HCT116 cells, though the activation of
caspase 2 was strongly suppressed in E6-expressing cells. This observation bolsters the
notion that caspase 2 acts upstream of the mitochondria in TR\IL-mediated cell death in
HCT116 cells and strengthens our conclusion that E6 targets apical events in the TRAIL
pathway in these cells.
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Given that some E6-expressing cells (e.g. SiHa) are resistant to TRAIL while
others (e.g. CasKi) are not (30), we examined the influence of E6 on apoptotic signaling
by TRAIL in a cellular model lacking other HPV proteins, such as E5, which can also
interfere with the pathway. The E5 protein has been shown to protect cells from both Fas
and TRAIL-mediated apoptosis, albeit by different mechanisms (19).

In their study,

Kabsch and Alonso showed that E5 inhibits Fas-induced apoptosis, in part, by decreasing
the cell surface expression of the Fas receptor. While E5 did not down-regulate TRAIL
receptor expression, it was found to inhibit TRAIL signaling by interfering with the
formation of the TRAIL DISC and thereby inhibiting the cleavage of pro-caspases 8 and
3, as well as of PARP. Given that E5 possesses weak transfonning activity (49) and is
most abundant prior to the integration of the F1PV 16 genome into the host DNA (50), it
may be important in the early stages of viral infection to create the conditions conducive
for viral propagation. In contrast, E6 is highly oncogenic and appears to perform the
majority of its functions post-integration, both in immune evasion and in tumorigenesis,
and while E6 binds to several proteins involved in apoptosis (26-29), no such interaction
has been demonstrated for E5.
Interestingly, we found that while transfection of E6 into HCT116 cells inhibits
TRAIL-induced apoptosis, it did not prevent cell death induced by TRAIL in all the
human cell lines that were tested (data not shown). For example, we observed that E6expressing clones derived from U20S osteosarcoma cells were sensitive to TRAIL
despite containing relatively high levels of E6.

This is consistent with the previous

observation regarding the response of Siffa and CasKi cells to TRAIL. One possible
explanation for the difference in the response of E6-expressing HCT116 and U20S cells
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to TRAIL may be that distinctive cellular characteristics predispose some cell-types, but
not others, to the anti-apoptotic actions of E6. Following a similar line of reasoning, it is
also likely that cell-type specific differences in the TRAIL pathway influence the ability
of E6 to block apoptosis and this raises the intriguing possibility that TRAIL may utilize
different signaling mechanisms in a manner dependant on the cellular context.
The ability of E6 to mediate the degradation of p53 is well established in the
literature and it is widely accepted that this phenomenon contributes to tumorigenesis by
altering cell survival (20, 21). This study further elucidates the mechanisms employed by
E6 to modulate cellular responses to death stimuli. Cell death induced by TNF, Fas and
TRAIL is transmitted through FADD and caspase 8 from cell surface receptors, to
executioner caspases.

By undermining the stability of these important signaling

molecules at the apex of the cascade, E6 is able to alter cell survival in a p53-independent
manner which may further contribute to tumorigenesis. Thus, HPV 16 appears to employ
both p53-dependent and -independent strategies to evade host defenses and avoid
elimination by the immune system.

59

Materials and Methods

Reagents

Lyophilized human recombinant Apo2L/TRAIL (Peprotech Inc., Rock Hill, NJ)
and TNF (R&D Systems, Minneapolis, MN) were dissolved in phosphate-buffered saline
(PBS) to yield 100 pg/ml and 1 pg/ml stocks, respectively; cycloheximide (Sigma, St.
Louis, MO) was prepared as a 5 mg/ml stock; C2-Ceramide (Biomol, Plymouth Meeting,
PA) was dissolved in dimethyl sulfoxide (DMSO) to yield a 25 mM stock; doxycycline
(Clontech, Palo Alto, CA) was dissolved in PBS to yield a 1 mg/ml stock; and Z-VADFMK (Biomol) was dissolved in DMSO to yield a 10 mM stock solution. Each of these
reagents were aliquoted and stored at -20°C prior to use. 3-[4,5-Dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) (Sigma) was dissolved in PBS, and mitomycin C
(Roche Molecular Biochemicals, Indianapolis, IN) was dissolved in DMSO to yield stock
concentrations of 5 mg/ml which were stored at 4°C until use.
Monoclonal antibodies directed against (3-actin and HA (Roche Molecular
Biochemicals) were dissolved in PBS to yield 400 pg/ml stock solutions and stored at
-20°C before use.

The mouse monoclonal, rabbit polyclonal and rat polyclonal

peroxidase-coupled anti-HA antibodies (Roche Molecular Biochemicals) were stored
under the same conditions prior to use.

Other antibodies used included antibodies

directed against Apaf-1, (BD Pharmingen), caspase 8 (BD Phanningen and Alexis
Biochemicals), GFP (Roche Molecular Biochemicals), PARP (Calbiochem) and p53
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(Novocastra Laboratories, Ltd, Newcastle, UK). These antibodies were stored at 4°C
until use.

Cell Culture

HCT116 (human colon carcinoma) cells were obtained from the ATCC
(Manassas, VA) and were cultured in McCoy's 5A medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen), penicillin (100 U/ml), and
streptomycin (100 pg/ml) (Sigma).

Plasmids

The pHA-E6S and pHA-E6AS plasmids have been described previously (29), and
respectively contain either the sense or the antisense versions of epitope-tagged E6 (HAE6) under the control of the CMV promoter. The following plasmids were obtained from
and described in the Tet-Off kit from Clontech: the pTet-Off plasmid, coding for tTA
(tetracycline activator); pTRE-luc, coding for luciferase under the control of the
tetracycline activator tTA; pTK-Hyg, coding for hygromycin resistance; and pTRE2, the
cloning plasmid. pTRE HA-E6 was obtained by cloning the Hindlll blunt end-BamHI
fragment from pHA-E6 S into the EcoRI blunt end-BamHI sites of the pTRE2 vector.
pcDNA3-FADD was kindly provided by Dr. Carl Ware (La Jolla Institute for
Allergy and Immunology, La Jolla, CA).
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pEGFP-1 was purchased from Clontech

Laboratories, Mountain View, CA and a CMV promoter construct was cloned into its
multiple cloning site for constitutive expression of GFP.

Cell Viability’ Assay

Following treatment of cells as described below, the incubation medium was
removed and exchanged with 80 pi of fresh medium. Twenty microliters of MTT was
then added (5 mg/ml stock), and cells were incubated at 37°C for 3 h. The medium was
removed, and 150 pi of DMSO was added and allowed to incubate for 10 min. The
solution was mixed by pipetting, and the absorbance of each well was measured at 490
nm.

Treatment of Cells with TRAIL, TNF, anti-Fas, Cycloheximide, Mitomycin C, Ceramide,
and Z-VAD-FMK

To measure cell survival following treatment with TRAIL and TNF, HCT116
cells were seeded in a 96-well plate (2 x 104 cells/well) and allowed to adhere overnight.
TRAIL (at the concentrations noted in text and figures) and TNF (5 ng/ml) were then
added in the presence of cycloheximide (1 to 5 pg/ml) and the cells were incubated for 16
h prior to measuring the number of viable cells by the MTT assay.
To detennine cell survival following mitomycin C and ceramide treatment, HCT
116 cells were seeded in a 96-well plate as described above (100 pi total volume) and
allowed to adhere overnight. For mitocmycin C treatment, fresh media containing the
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indicated concentrations of the genotoxin was added to the wells, and the cells were
incubated for 24 h before measurement of the number of viable cells by the MTT assay.
Prior to ceramide treatment, spent media was removed and replaced with media
supplemented with 2% serum. Ceramide was then added to the indicated final
concentrations, and the cells were incubated for 24 h prior to measurement of the number
of viable cells by the MTT assay.
To determine whether cell death following TRAIL treatment was caspase
dependent, HCT116 cells were treated with cycloheximide (5 pg/ml) and TRAIL in the
presence or absence of Z-VAD-FMK (50 pM). Finally, the effect of E6 on the levels of
FADD and pro-caspase 8 were detennined by treating HCT116 cells containing or
lacking E6 with cycloheximide (5 pg/ml) for the indicated hours.

Transfections

Transfections (except with siRNA) were carried out using FuGENE VI (Roche
Molecular Biochemicals), as directed by the manufacturer. For transient transfections.
cells were analyzed 40-48 h post-transfection.

For stable transfections, clones were

passaged into selection medium containing G418 (500 pg/ml) 72 h post-transfection.
Individual clones were selected, grown and analyzed for protein expression by
immunoprecipitation and immunoblotting.
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Immunoblotting

Cells (2 x 106) were lysed in 100 (ill of lysis buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% Triton X-100, 1 mM EDTA, 5% glycerol, 1 mM DTT, 1 mM PMSF) for
10 min on ice. One tablet of protease inliibitor mixture (Roche Applied Science) per 10
ml of lysis buffer was added just prior to use. The protein concentration in cleared lysates
was measured using the Bio-Rad Protein Assay (Bio-Rad).
Lysates (40 pg total protein/lane) were then subjected to 12% SDS-PAGE and
transferred to Immobilon P membranes (Millipore Corp.). After treating the membranes
with 5% nonfat milk in TBST (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween 20),
primary antibodies were applied and membranes were incubated for 1 h, with rocking, at
room temperature. After washing with TBST, peroxidase-coupled secondary antibodies
were added for detection. The membranes were then washed again with TBST following
1 h of incubation in the secondary antibodies. Detection of the proteins was performed by
using the chemiluminescent SuperSignal West Femto or Pico Maximum Sensitivity
substrate (Pierce).

Immunoprecipitation

HCT116 cells (2-5 x 106) were lysed in 500 pi of the immunoblotting lysis buffer,
and cleared lysates were incubated with 2 pg of monoclonal anti-HA antibody (Roche
Molecular Biochemicals) at 4°C for 1 h with rotation. Protein A/G-agarose slurry (50 pi)
(Santa Cruz Biotechnology, Santa Cruz, CA) was added to each lysate, and lysates were
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incubated for 2 h at 4°C. The protein A/G slurry was then washed three times with lysis
buffer, followed by one wash with high salt buffer (50 mM Tris-HCl, pH 7.5, 0.5 M
NaCl, 0.1% Nonidet P-40, 1 mM EDTA, 1 mM DTT) and one wash with the same buffer
lacking NaCl.

The precipitates were fractionated

by

12%

SDS-PAGE, and

immunoblotting was performed as described above.

Morphological Analysis ofApoptotic Cells

Cells were seeded on cover slips in a 6-well plate and allowed to incubate
overnight.

The following day, they were treated with 50 ng/ml TRAIL plus

cycloheximide (5 pg/ml). After the indicated time points, slides were fixed in a solution
of 4% paraformaldehyde in PBS, then mounted using Vectashield mounting medium with
4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc. Burlingame, CA). The
morphology of these cells was then analyzed by phase-contrast microscopy (Olympus
BX50, Japan). The DAPI-stained nuclei were monitored using the UplanFI objective at a
magnification of 1000X.

The percentage of apoptotic cells was expressed as the

percentage of cells exhibiting condensed nuclei and/or nuclei with fragmentations as
compared to the total number of nuclei examined. At least 100 nuclei were counted for
each determination. Percentages represent an average of three determinations.
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Development and Use of the Tet-Off System

HCT116 cells capable of expressing variable amounts of HA-E6, regulated by the
dose of drug present in the media, were created using the Tet-Off system (Clontech)
according to the manufacturer's protocol with some modifications (29). Cultures of these
cells were grown in the indicated concentrations of doxycycline for two days prior to use,
and the indicated concentrations of doxycycline were maintained in the media throughout
each experiment.

RT-PCR

The reverse transcriptase-polymerase chain reaction was used to analyze the HAE6 message in the HCT116 Tet-Off cell line.

cDNA was synthesized by using

Superscript™ II reverse transcriptase (Invitrogen) and an oligo(dT) primer (Amersham).
PCR was then employed to amplify full-length E6 with primers for the 5’ (5'-

GC ACC AAAAGAGAACT GC AAT GT-3)'

and

3’

(5'-

TGGGTTTCTCTACGTGTTCTTGAT-3') end of the sequence, using 1/20 of the total
cDNA reaction mixture. Additionally, the Cofilin 1 (CFL1) message was amplified to
normalize E6 levels with primers specific for CFL1.

To control for possible

contamination by genomic DNA, parallel reactions were run using 0.175 pg of total RNA
in the absence of the reverse transcriptase enzyme.
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Targeted Silencing of Gene Expression Using SiRNA

Transfection of cells with control siRNA (random sequence) (Dhannacon
Research, Inc., Lafayette, CO) and FADD siRNA (Santa Cruz Biotechnology) was
performed according to the manufacturer’s protocol. Cells were seeded in media lacking
antibiotics and incubated at 37°C overnight.

The transfection mixtures were then

prepared by adding siRNA to siTransfection Medium (Santa Cruz Biotechnology) in one
tube and siTransfection Reagent (Santa Cruz Biotechnology) to siTransfection Medium
(Santa Cruz Biotechnology) in another tube and incubating the contents of the tubes at
room temperature for 5 min. The amounts of the reagents were calculated based on the
values indicated in the protocol and were scaled up or down in proportion to the surface
area of the plate.

After 5 min, the mixtures were combined and incubated at room

temperature for 20 min to facilitate the development of a siRNA-siRNA Transfection
Reagent Complex. During this time, the media covering the cells was replaced with fresh
media without antibiotics and at the end of the 20 min incubation, the complex was added
to the cells. The cells were then incubated at 37°C for 24-30 h.
To verify that siFADD was reducing the expression of exogenous FADD, the
cells were seeded in a 6-well plate at a density of 2.5 x 105 cells/well and transfected with
siControl or siFADD as described above. Afterward, the cells were transfected with
pcDNA3-FADD and pE-lCMV-GFP and incubated for 24-48 h at 37°C. The expression
of FADD and GFP was then analyzed by immunoblot.
To measure the survival of siFADD-expressing cells following treatment with
TRAIL, cells were seeded in a 96-well plate at a density of 1.8 x 104 cells/well and
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transfected with siControl or siFADD as described above. The cells were then treated
with TRAIL (50 ng/ml) in the presence of cycloheximide (5 pg/ml) for 16 h and cell
viability was determined by the MTT assay.

Caspase 8, 3, and 2 Assays

Cells were plated into black 96-well plates at a density of 2 x 104 cells per well
and incubated overnight. TRAIL (50 ng/ml) was then added, along with cycloheximide (1
or 5 pg/ml) for the times indicated. Caspase activity was then measured using the
flourogenic substrate IETD-AMC for caspase 8, DEVD-AMC for caspase 3 and
VDVAD-AMC for caspase 2 (Alexis Biochemicals) as described (51). Briefly, cells (in a
total volume of 40 pi media/well) were lysed by the addition of 20 pi of 3X lysis buffer
(150 mM HEPES, pH 7.4, 450 mM, NaCl, 150 mM KC1, 1.2 mM EGTA, 1.5% Nonidet
P40, 0.3% CHAPS, 30% sucrose, 30 mM DTT, 3 mM PMSF) which included either
substrate alone (150 pM) or substrate plus inhibitor (2 pg/ml). The inhibitors for caspases
8, 3 and 2 were IETD-CHO (BD Pharmingen), DEVD-CHO (Alexis Biochemicals) and
VDVAD-CHO (Alexis Biochemicals), respectively. After 2, 4 and 6 h of incubation for
caspases 3 and 8, and 3 and 6 h of incubation for caspase 2, the released fluorochrome
was measured with a plate-reading fluorimeter (Flx800, Bio-Tek Instrument Co) using an
excitation of 360 nm and an emission of 460 nm. The activity in wells treated with the
inhibitor was subtracted from the activity in wells lacking the inhibitor. The resulting
difference was expressed as a percentage of caspase activity in the untreated parental
cells. Data from three independent experiments are shown, and error bars represent the
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standard deviation.

Statistical Analysis

Data were analyzed using the unpaired t test on a GraphPad Prism software
package for Windows (GraphPad Software Inc.). A P value of <0.05 was considered
statistically significant.
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Abstract

The tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/Apo2L is a
cytotoxic protein that induces apoptosis in many malignant cell types. In this study, we
used the human papillomavirus (HPV) 16 E6 protein as a molecular tool to probe the
TRAIL pathway in HCT116 colon carcinoma cells and U20S osteosarcoma cells.
Intriguingly, we found that while E6 protected HCT116 cells from TRAIL, U20S cells
containing E6 remained sensitive to TRAIL.

Furthermore, silencing FADD and

procaspase-8 expression with small interfering (si)RNA did not prevent TRAIL-induced
apoptosis in U20S cells. However, siBid provided significant protection from TRAIL in
these cells, and the cleavage kinetics of Bid and caspase-8 revealed that Bid was cleaved
prior to the activation of caspase-8 in this cell death cascade. Although Bid cleavage has
been implicated in the Jun N-terminal Kinase (JNK) and ceramide pathways, neither
pathway was found to contribute to TRAIL-induced apoptosis in U20S cells. However,
analysis of cathepsin B activity in these cells revealed that it was significantly activated
shortly after exposure to TRAIL. Additionally, the cathepsin B inhibitor, CA074Me,
inhibited both TRAIL- and anti-DR5-mediated apoptosis and delayed the cleavage of Bid
in U20S cells exposed to TRAIL. These findings suggest that TRAIL activates a mostly
FADD/caspase-8 independent pathway in U20S celts.
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Introduction

Cell death mediated by tumor necrosis factor (TNF)-related apoptosis inducing
ligand (TRAIL) has been a topic of intense investigation ever since the discovery of
TRAIL in the mid-1990’s. To date, TRAIL remains unrivaled in its ability to suppress
tumor growth and eliminate tumors with minimal toxicity to normal tissue.

For this

reason, the mechanisms of TRAIL-induced cell death have been vigorously researched to
uncover targets with therapeutic potential.
The cytotoxic ligand, TRAIL, is a member of the TNF superfamily and although
it is expressed as a type II membrane protein its extracellular domain can be
proteolytically cleaved to generate a soluble form of the ligand (52). TRAIL binds to five
receptors (reviewed in 32).

Two of these receptors, DR4 (TRAIL-R1) (3) and DR5

(TRAIL-R2) (4) possess a conserved death domain (DD) motif and are thus capable of
transmitting death signals from TRAIL.

However, the other three receptors are not

capable of transmitting death signals from TRAIL. Osteoprotegerin (OPG) is a secreted
member of the TNF superfamily and is the only soluble TRAIL receptor (53); DcRl
(TRAIL-R3) (54) lacks both transmembrane and death domains and is anchored to the
cell surface by a glycophosphatidyl inositol tail while DcR2 (TRAIL-R4) (55) has a
truncated, nonfunctional DD.

DcRl and DcR2 were designated as decoy receptors

because they could compete with DR4 and DR5 for binding to TRAIL when
overexpressed (5).

Although cells express different levels of the TRAIL receptors,

receptor expression seldom correlates with sensitivity to TRAIL.
TRAIL-induced apoptosis is initiated by the binding of TRAIL to DR4 and/or
DR5. This interaction leads to the recruitment of adaptor proteins and initiator caspases

81

to the DDs of the receptors resulting in the fonuation of a death inducing signaling
complex (DISC).

Until recently, the exact composition of the TRAIL DISC was

unknown due to conflicting reports in the literature regarding the role of certain
intracellular signaling proteins in the TRAIL apoptotic pathway.

By far, the most

controversial of these proteins has been the adaptor protein Fas-associated death domain
(FADD). Shortly after the discovery of TRAIL, several groups using co-transfection/coimmunoprecipitation techniques were unable to demonstrate binding between FADD and
DR4 or DR5 (3-5, 56) while similar experiments by other groups were successful (57,
58).

Adding to the controversy was the discovery by Yeh and others that FADD-

deficient embryonic mouse fibroblasts (MEFs) were sensitive to apoptosis induced by the
overexpression of DR4, suggesting that FADD was not essential for signal transduction
by DR4 (59). However, evidence from two groups that isolated the native TRAIL DISC
from untransfected cells, confirmed the participation of both FADD and caspase-8 in the
apical events of the TRAIL apoptotic pathway (7, 8). Caspase-8, an initiator caspase, is
recruited by FADD to the DISC and is activated by autoproteolysis resulting in its
cleavage and dissociation from the DISC, and the commencement of downstream events
in this cell death pathway (32).
As in Fas-mediated apoptosis, the events following the activation of caspase-8 in
the TRAIL pathway depend on the cell type. In some cells (so-called type 1) caspase-8
activation is sufficiently robust to directly cause the cleavage of caspase-3 while in other
cells (so-called type 2) the death signal must be amplified via the activation of the
mitochondrial apoptotic pathway because the activation of caspase-8 is weak (60). The
pro-apoptotic Bcl-2 family member. Bid, is the link between the death receptor and
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mitochondrial apoptotic pathways (32). The cleavage of Bid by caspase-8 leads to the
penneablization of the outer membrane of the mitochondria and the release of
cytochrome c. Cytochrome c then forms a complex with apoptosis protease activating
factor (Apaf)-1 and procaspase-9 called the apoptosome. The apoptosome is analogous
to the DISC in the death receptor pathway and its formation results in the activation of
caspase-9 which, in turn, activates caspase-3. Once activated, caspase-3 cleaves cellular
substrates such as poly(ADP-ribose) polymerase (PART) and Lamin B, bringing about
the demise of the cell.
There is a preponderance of evidence, however, which suggests that TRAILmediated apoptosis differs from the Fas-model in many cell types. One example is an
elegant theory proposed by Douglas Green in which he suggests that thymocyte apoptosis
(negative selection), an essential immunological event believed to be mediated by
TRAIL, occurs in a Jun N-tenninal Kinase (JNK)-dependent manner and without the
involvement of FADD or caspase-8 (61). Indeed, the binding of TRAIL to its receptors
can activate the INK pathway (62) and there is strong evidence that JNK can transmit
pro-apoptotic signals (63).

Ceramide and other sphingolipid species have also been

shown to participate in TRAIL-mediated apoptosis. In a recent study, defects in the
ceramide pathway were associated with resistance to TRAIL in metastatic colon cancer
cells (64).

In another study, sphingosine and TRAIL triggered Bax activation with

similar kinetics in rhabdomyosarcoma cells; however, inhibiting caspase-8 activity did
not prevent their respective apoptotic pathways, implying that sphingosine can mediate
TRAIL-induced apoptosis in a caspase-8-independent manner (65).
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The ability of lysosomal proteases to influence death receptor apoptotic pathways,
including apoptosis mediated by TRAIL, has also been documented in the literature.
Cathepsins B and D, for example, have been shown to modulate cellular responses to
TNF (66, 67). Recently, it was reported that TRAIL-induced apoptosis in oral cancer
cells is mediated by cathepsin B, and that the cleavage of Bid by cathepsin B is an
important event in this pathway (68). These studies illustrate the complexity of the
TRAIL apoptotic pathway in different cellular models.
We have shown that the human papillomavirus (HPV) 16 E6 impairs TRAILmediated apoptosis in HCT116 colon cancer cells by accelerating the degradation of
FADD and capase-8 (69). This finding suggests that FADD and caspase-8 are necessary
for TRAIL-mediated apoptosis in HCT116 cells. In this report, we used HPV 16 E6 as a
molecular tool to probe the TRAIL pathway in U20S osteosarcoma cells. Our results
demonstrate that neither transfection of E6 nor small interfering (si)RNA targeting
FADD and caspase-8 protect U20S cells from TRAIL, suggesting that these proteins do
not play a major role in the TRAIL apoptotic pathway in U20S cells. Furthermore, the
cleavage of Bid occurs prior to the activation of caspase-8 and can be blocked by pre
treating the cells with a highly specific inhibitor of cathepsin B (CA074Me).

This

finding suggests that apoptosis induced by TRAIL in U20S cells is mediated by
cathepsin B, and that the cleavage of Bid is the limiting step in the pathway. Our study
therefore contributes to a growing body of evidence supporting the role of lysosomal
proteases in death receptor-induced apoptosis, and also reinforces the conclusion that a
diversity of TRAIL-mediated pathways exist and can be employed in a cell type-specific
manner.
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Results

HPV16 E6 Protects HCT116, but not U20S Cells from TRAJL-mediated Cell Death

Our previous work showing that HPV 16 E6 can block TNF- and anti-Fasinduced apoptosis in human cells (28, 29) led us to speculate that E6 might also inhibit
apoptotic signaling by TRAIL since TNF, FasL (Fas ligand) and TRAIL are thought to
share a common signaling mechanism. Indeed, we found that transfection of HPV 16 E6
into the human epithelial cell line HCT116 provided protection from TRAIL-mediated
apoptosis in a dose-dependent manner (69). The mechanism of protection involved a
rapid reduction in the cellular levels of FADD and procaspase-8, two important signaling
molecules in the pathway that are targeted by E6. This finding implies that E6 can
exploit similarities between the pathways triggered by these death ligands.
To determine whether E6 protects other cell types from TRAIL-mediated
apoptosis, we examined the response of U20S cells expressing E6 to TRAIL. Stable
pools derived from HCT116 and U20S cells expressing either the sense or antisense
versions of epitope-tagged HA-E6 (HA-E6S and HA-E6AS, respectively) were treated
with TRAIL/cycloheximide (CHX) to determine their sensitivity to TRAIL-induced cell
death.

Interestingly, while the HCT116 HA-E6S pool (HCT116E6SP), but not the

HCT116 HA-E6AS pool (HCT116E6ASP), experienced protection from TRAILmediated cell death, the stable pool derived from sense-transfected U20S cells
(U20SE6SP) was as sensitive to TRAIL as was the stable pool derived from antisensetransfected U20S cells (U20SE6ASP) (Figure 9A). To further explore this finding.
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Figure 9. HPV 16 E6 protects HCT116, but not U20S cells from TRAIL-mediated cell
death. HCT116 and U20S cells were transfected with either HA-E6S or HA-E6AS to
create stable pools and clones. Parental cells as well as HA-E6S and HA-E6AS pools
and clones were incubated with TRAIL for 16 h in the presence of CHX. After 16 h, cell
survival was measured by the MTT assay. Each data point represents three independent
replicates, and the error bars represent the standard deviation. (A) Response of HCT116
and U20S HA-E6S and HA-E6AS pools to TRAIL (50 ng/ml).
P < 0.05 versus
HCT116E6ASP treated with 50 ng/ml TRAIL. B) Response of HCT116 and U20S HAE6AS and HA-E6S clones to TRAIL (50 ng/ml).
P < 0.001 versus HCT116E6ASP
treated with 50 ng/ml TRAIL. (C) Immunoprecipitation/immunoblot analysis of HA-E6
expression in parental HCT116 cells (Lane 1) as well as HCT116 (HCT116E6S29, Lane
2) and U20S (U20SE6AS9, Lane 3; U20SE64b, Lane 4) clones. (D) Response of
U20SE6tet24 cells cultured in the absence of doxycycline (dox) or 0.4, 1 or 4 ng/ml dox
to TRAIL (50 ng/ml). Immunoprecipitation/immunoblot analysis of HA-E6 expression
in U20SE6tet24 cells cultured in the absence of dox or 4 ng/ml dox was also shown.
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individual clones derived from both cell lines were subjected to treatment with
TRAIL/CHX. As expected, HCT116 cells stably expressing HA-E6S (HCT116E6S29)
were significantly more resistant to TRAIL than the antisense-expressing cells
(HCT116E6ASP) (90.4% versus 26.0% viability) (Figure 9B).

However, E6 did not

protect U20S cells from TRAIL even though HA-E6S protein expression was detectable
in clone 4b (U20SE64b) by immunoprecipitation/immunoblot (Figure 9C).
As noted earlier, the degree of protection provided to E6-expressing HCT116
cells from TRAIL is directly proportional to the level of expression of E6 (69). Thus, to
account for clonal variability in the U20SE64b clone, we assessed the effect of
TRAIL/CHX treatment on the viability of U20S cells containing HA-E6S under the
control of a doxycycline-inducible promoter. We found that even at maximal levels of
E6 (no dox) the cells remained sensitive to TRAIL/CHX (Figure 9D). Taken together.
these findings demonstrate that E6 can protect some, but not all human cells from
TRAIL-induced cell death.

TRAIL Kills U20S Cells by a Caspase-dependent Apoptotic Mechanism

Our discovery that E6 inhibits TRAIL-mediated cell death in HCT116 cells but
not U20S cells opened up the possibility that the TRAIL cell death pathway occurs by
different mechanisms in these cell lines (i.e., apoptosis, necrosis, etc.). This notion was
supported by our observation that U20S cells die more quickly than HCT116 cells under
the same conditions of TRAIL/CHX treatment (Figure 10A).

To determine the

mechanism of TRAIL ki lling in U20S cells, we treated the cells with CFIX alone or CHX
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Figure 10. TRAIL-mediated cell death in U20S cells occurs by apoptosis and is capasedependent. (A) HCT116 and U20S cells were treated with TRAIL (100 ng/ml) in the
presence of CHX for 0, 0.5, 1, 2 and 4 h and then subjected to the MTT assay to
determine cell viability. Each data point represents three independent replicates, and the
error bars represent the standard deviation. (B) U20S cells were seeded on coverslips in
6-well plates and treated with TRAIL (50 ng/ml), anti-DR5 (50 ng/ml) and anti-Fas (50
ng/ml) plus CHX for 2 h (TRAIL) and 6 h (anti-DR5 and anti-Fas), respectively. After
fixation in 4% paraformaldehyde, the slips were mounted using Vectashield mounting
media with DAPI. Morphology of cells was analyzed by phase-contrast microscopy, and
the DAPI-stained nuclei monitored using a UPA1FI objective. The cells in each panel
were magnified 1000 x with the oil immersion lens. For each set of three panels, the
lower panel represents phase contrast microscopy, the middle panel the DAPI staining
pattern, and the top panel a merged image. The green background in the merged image is
due to the light used to obtain a visible image.
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Subsequently, the cells were

stained with 4,,6-diamidino-2-phenylindole (DAPI) and their morphology was examined
by phase-contrast microscopy.

Nuclear fragmentation and cytoplasmic blebbing, both

hallmarks of apoptosis (70), were seen in cells treated with all three proteins indicating
that TRAIL induces apoptosis in U20S cells (Figure 10B). To confirm that the cells
were dying by apoptosis in response to TRAIL, we examined the cleavage of poly(ADPribose)polymerase (PARP) and Lamin B in U20S cells treated with TRAIL/CHX for 3,
6, 9 and 12 h. During staurosporine (STS)-induced apoptosis in U20S cells, PARP and
Lamin B are cleaved into 89kD and 46kD fragments, respectively (71).

In contrast,

apoptotic fragments of PARP and Lamin B are not produced during tert-butyl
hydroperoxide (TBH)-mediated necrosis (71). We found that the pattern of cleavage of
these proteins was consistent with apoptotic cell death following exposure to
TRAIL/CHX (Figure 10C). However, while the major cleavage fragments of both PARP
and Lamin B appeared at 6 h, there was a significant decrease in the full length fonn
(116kDa) of PARP within 3 h of treatment with TRAIL/CHX (Figure 10C).
The requirement for caspase activation was also examined. In this experiment,
U20S cells were treated with TRAIL/CHX alone or in the presence of Z-Val-AlaAsp(OMe)-Flourmethylketone (z-VAD-fmk). We found that in the presence of z-VADfmk, U20S cells experienced significant protection from TRAIL-mediated apoptosis
(Figure 10D).

Together, these data demonstrate that TRAIL-mediated cell death in

U20S cells occurs by apoptosis and is caspase-dependent.
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Figure 10. (C) U20S cells were treated with TRAIL (50 ng/ml) in combination with
CHX for the indicated times and then lysed. Subsequently, the lysates were analyzed for
PARP and Lamin B cleavage by immunoblot. p-actin expression was used a loading
control. (D) U20S cells were treated with CHX alone or the indicated combinations of
CHX, TRAIL (50 ng/ml) and Z-VAD-FMK (50 pM) for 16 h. After 16 h, the percentage
of viable cells was determined by the MTT assay. Each data point represents three
independent replicates, and the error bars represent the standard deviation. **P < 0.01
versus U20S cells treated with CHX and TRAIL alone.
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CHX + TRAIL+ ZVAD

U20S Cells Express Detectable Levels ofDR5 but Virtually No DR4

Our finding that TRAIL induces caspase-dependent apoptosis in U20S cells, but
that this pathway is refractory to inhibition by E6 raised the intriguing possibility that
TRAIL induces different apoptotic pathways in U20S than in HCT116 cells. Therefore,
we decided to interrogate the TRAIL pathway in U20S cells by first examining the
expression of DR4 and DR5.
The expression of DR4 and DR5 on the cell surface of U20S and HCT116 cells
was examined by flow cytometric analysis. HCT116 cells were used as a positive control
because they express relatively high levels of both DR4 and DR5 (8). As expected, flow
cytometry confirmed the expression of both DR4 and DR5 receptors on HCT116 cells.
However, much less receptor expression was detected on the U20S cells (Figure 11 A).
The specific mean fluorescence of each receptor was calculated for each cell line and the
results revealed that HCT116 cells had ~ 40 times (6.3 versus 0.17) more DR4 than
U20S cells and —10 times (13.7 versus 1.5) more DR5 than U20S cells (Figure 11B).
We then examined DR4 and DR5 protein levels in the two cell lines by immunoblot.
Consistent with the results from flow cytometry, the immunoblot data demonstrated high
levels of DR4 and DR5 in HCT116 cells relative to U20S cells (Figure 11C).
To verify the contribution of DR4 and DR5 to apoptotic signaling by TRAIL in
U20S cells, the cells were pretreated with DR4 and/or DR5 monoclonal antibodies and
then treated with TRAIL/CHX. The purpose of pretreating the cells with these antibodies
was to block access by TRAIL to its binding site on DR4 and DR5, so that the induction
of the TRAIL apoptotic pathway through each receptor could be examined separately.
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Figure 11. U20S cells express detectable levels of DR5 but virtually no DR4 on their
cell surface. (A) Flow cytometric analysis of DR4 and DR5 expression on the cell
surface of HCT116 and U20S cells. The green line represents staining with both primary
and FITC-conjugated secondary antibodies while the red line represents staining with
FITC-conjugated secondary antibodies alone. The later was used as a negative control.
(B) Specific mean fluorescence (SMF) of DR4 and DR5 expression on FICT116 and
U20S cells. SMF was calculated by subtracting the mean fluorescence of cells stained
with secondary antibody alone from the mean fluorescence of cells stained with both
primary and secondary antibodies. (C) Immunoblot analysis of DR4 and DR5 expression
in HCT116 and U20S cells. P-actin expression was used a loading control.
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Interestingly, we found that cells preteated with DR4 monoclonal antibodies were
sensitive to TRAIL (as were cells treated with no antibodies) while cells pretreated with
DR5 monoclonal antibodies were resistant to TRAIL (as were cells pretreated with both
DR4 and DR5 antibodies) (Figure 11D).

In addition to protecting U20S cells from

TRAIL, we found that the DR5 monoclonal antibodies could also induce a dosedependent decrease in cell viability in the presence of the protein synthesis inhibitor CHX
(Figure HE).

These data suggest that DR5 is primarily responsible for transmitting

apoptotic signals from TRAIL in U20S cells and that the DR4 pathway is either
nonfunctional or weak due to low cell surface expression of the receptor.

FADD and Caspase-8 are not the Primaiy Mediators of TRAIL-induced Apoptosis in
U20S Cells

The Fas apoptotic pathway is the most straightforward and best understood death
receptor pathway. Generally, both FADD and caspase-8 are required for Fas-mediated
apoptosis, which can be induced by the FasL (72) or antagonistic anti-Fas antibodies
(73). TRAlL-mediated apoptosis is not as well understood but is thought to be similar to
the Fas model in its requirement for FADD and caspase-8 (7, 8). Our recent report that
TRAIL-mediated apoptosis in HCT116 cells is impaired by the ability of E6 to decrease
the half-life of FADD and caspase-8 supports this conclusion (69). However, E6 does
not inhibit the TRAIL pathway in U20S cells, which suggests that FADD and caspase-8
may be dispensable for TRAIL-mediated apoptosis in these cells.
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Figure 11. (D) Response of U20S cells pretreated with no antibody, anti-DR4, anti-DR5
P < 0.001 versus
or anti-DR4/DR5 to TRAIL (100 ng/ml) in the presence of CHX.
U20S cells pretreated with no antibody. (E) Response of U20S cells to CHX alone or
CHX plus 5, 25, 50, 100 and 500 ng/ml anti-DR5. For D and E, treatment with TRAIL
or anti-DR5 was performed for 16 h. After 16 h, cell viability was determined by the
MTT assay. Each data point represents three independent replicates, and the error bars
represent the standard deviation.
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To determine the importance of FADD and caspase-8 to TRAIL signaling in
U20S cells, we examined the response of U20S cells deficient in FADD and procaspase8 to treatment with TRAIL and anti-Fas.

We found that while transfection of small

interfering (si)RNA targeting FADD and procaspase-8 (siFADD and siCaspase-8,
respectively) in U20S cells provided strong protection from anti-Fas mediated apoptosis.
the same cells experienced only weak to moderate protection from TRAIL (Figure 12A).
Immunoblot analysis of FADD and procaspase-8 levels in the transfected cells showed
significant inhibition of their protein expression (Figure 12B). To further examine the
role of caspase-8 in the TRAIL signaling pathway in U20S cells, we compared the
activation of caspase-8 in U20S and HCT116 cells following treatment with TRAIL.
Caspase-8 activation in HCT116 cells was used as a control because these cells
experience a rapid increase in caspase-8 activity shortly after exposure to TRAIL/CHX
(69). As expected, there was a rapid increase in caspase-8 activity in HCT116 cells 0-4 h
after exposure to TRAIL (Figure 12C). Flowever, the activity of caspase-8 in U20S cells
was very weak (Figure 12C) even though these cells died more quickly than HCT116
cells during the same time period. Together, these data suggest that FADD and caspase-8
do not play a major role in TRAIL-mediated apoptosis in U20S cells.

Bid Cleavage Occurs Prior to the Activation of Caspase-8 During TRAIL-mediated
Apoptosis in U20S cells

In some cell types, TRAIL signaling leads to the cleavage of Bid by caspase-8
generating a truncated version of the protein which in turn activates the
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Figure 12. FADD and Caspase-8 do are not major mediators of TRAIL-induced
apoptosis in U20S cells. (A) U20S cells were transfected with non-specific, control
siRNA (siControl), siFADD and/or siCaspase-8 and incubated at 37°C for 24 h.
Following incubation, the siFADD transfected cells were also transfected with pcDNA3FADD and all cells were incubated at 37°C for an additional 24 h. The cells were then
treated with anti-Fas (50 ng/ml) or TRAIL (50 ng/ml) for 16 in the presence of CHX.
After 16 h, cell survival was measured by the MTT assay. Each data point represents
three independent replicates, and the error bars represent the standard deviation. **P <
0.01; P < 0.001 versus siControl-transfected cells treated with anti-Fas. (B) siRNAmediated knockdown of FADD and procaspase-8 protein expression is also shown.
Transfection of siControl, siFADD, and siCaspase-8 in U20S cells was performed as
described above. However, pE-lCMV-GFP was co-transfected with pcDNA3-FADD.
The cells were then lysed, and the lysates were analyzed for the expression of FADD and
caspase-8 by immunoblot. P-actin and GFP expression was used as a loading control.
(C) HCT116 and U20S cells were treated with TRAIL (50 ng/ml) in combination with
CHX for the indicated time intervals and then lysed. Subsequently, the lysates were
incubated with the flourogenic substrate for capases 8 (Ac-IETD-pNA) in the presence or
absence of the capase-8 inhibitor, Ac-IETD-CHO. The released fluorochrome was
measured with a fluorimeter. Percent caspase activity was calculated by subtracting the
activity in wells containing inhibitor from the activity in wells lacking inhibitor and
expressing this number as a percentage of caspase activity in wells containing untreated
cells. Each data point represents three independent replicates, and the error bars
represent the standard deviation. ***P < 0.001 versus caspase-8 activity of U20S cells at
4 h.
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mitochondrial apoptotic pathway (32). A key event in this signaling pathway is the
release of cytochrome C which leads to the activation of caspase-9 and downstream
executioner caspases such as caspase 3 and 7. Once activated, these executioner caspases
cleave a number of substrates including Lamin B and PARP. Thus, the cleavage of Bid is
a critical step in bridging the extrinsic and intrinsic (mitochondrial) components of the
TRAIL apoptotic pathway.
To further explore the mechanism of TRAIL-mediated apoptosis in U20S cells.
we examined the cleavage kinetics of caspase-8, Bid, caspase-3 and PARP. U20S cells
were treated with TRAIL/CHX for 0.5, 1, 2 and 4 h and lysed. Subsequently, the levels
of these proteins in the cell lysates were analyzed by immunoblot. As a control, the same
experiment was performed with HCT116 cells and the results from the two cell lines
were compared.

We found that the expression patterns of the indicated signaling

molecules in HCT116 cells exposed to TRAIL was typical of a type II cell line. In these
cells, caspase-8 cleavage occurred early (0.5 h) followed by a gradual reduction in levels
of Bid and procaspase-3 between 0 and 4 h, and a substantial decrease in the 116 kDa
form of PARP between 2 and 4 h (Figure 13A). A faint band, representing the cleaved
form of PARP (89 kDa), could also be detected at 4 h. Not surprisingly, the cleavage
kinetics of these proteins in U20S cells did not comply with this pattern. Following
exposure to TRAIL, there was a much more rapid decline in Bid and procaspase-3 levels
between 0 and 0.5 h while the cleaved forms of caspase-8 (p43/41) did not appear until
the 2 h time point (Figure 13A). This time point was also when the 89 kDa fragment of
PARP was first seen (Figure 13A), indicating that the cells were already in the final phase
of apoptosis.

103

Figure 13. Bid cleavage occurs prior to the activation of caspase-8 during TRAILmediated apoptosis in U20S cells. (A) Cleavage kinetics of Bid, caspase-8, caspase-3
and PAR? in response to treatment with TRAIL (50 ng/ml) and CHX. The expression of
the indicated proteins was analyzed by immunoblot and p-actin expression was used a
loading control. The cleavage product of Bid could not be detected; therefore, decreases
in the amount of full-length Bid were monitored. (B) U20S cells were transfected with
non-specific, control siRNA (siControl) or siBid and incubated at 37°C for 24 h. After 24
h, cells were treated with TRAIL (50 ng/ml) in the presence of CHX for 16 h. Cell
survival was then measured by the MTT assay. Each data point represents three
independent replicates, and the error bars represent the standard deviation.
P < 0.001
versus siControl-transfected cells treated with TRAIL. (C) Transfection of siControl and
siBid in U20S cells was performed as described above. The cells were then lysed, and
the lysates were analyzed for the expression of Bid by immunoblot. P-actin protein
expression was used a loading control.
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Our finding that Bid cleavage occurs before the processing of caspase-8 in
TRAIL-treated U20S cells suggested that the activation of Bid might be the limiting step
in this pathway.

To assess the importance of Bid in this pathway, U20S cells were

transfected with control siRNA (siCont) or siBid and then treated with TRAIL or antiFas.

We found that siBid strongly inhibited TRAIL-mediated apoptosis but only

provided marginal protection from apoptotic signaling by anti-Fas (Figure 13B).

To

verify that siBid inhibits Bid expression, Bid levels in the transfected cells were analyzed
by immunoblot. The results show that siBid significantly attenuates the expression of
Bid in U20S cells (Figure 13C). Together, these data demonstrate that the activation of
Bid is essential for TRAIL-mediated apoptosis in U20S cells.

TRAIL-induced Apoptosis in U20S Cells is not Mediated by JNK or Ceramide

Bid cleavage has been implicated in the signaling pathways of both JNK (74) and
ceramide (75), and these pathways can contribute to TRAIL-mediated apoptosis in some
cell types (63, 64). To explore the role of the JNK and ceramide pathways in TRAIL
apoptotic pathway in U20S cells, we incubated the cells with inhibitors of each pathway
and then assessed their sensitivity to TRAIL. To inhibit the JNK pathway, we pretreated
cells with SP600125, a potent, selective inhibitor of JNK-1, -2 and -3 (76). SP600125
did not block cell death triggered by TRAIL in U20S cells (Figure 14A), which suggests
that JNK is not an important mediator of the TRAIL apoptotic pathway in these cells.
Next, we examined the role of the ceramide pathway in TRAIL-mediated apoptosis in
U20S cells. A key event in the ceramide pathway is the synthesis of ceramide (77).
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Ceramide can be synthesized de novo or by the conversion of sphingomyelin to ceramide
by sphingomylinase. Three inhibitors were used to block ceramide production: myriocin
(ISP-1), which inhibits the de novo synthesis of ceramide, and imipromine and
desipramine, which inhibit the breakdown of sphingomyelin. Neither inhibition of de
novo ceramide synthesis nor the conversion of sphinomyelin to ceramide altered the
sensitivity of U20S cells to TRAIL (Figure 14B, C and D). These data demonstrate that
the JNK and ceramide pathways do not contribute significantly to apoptotic signaling by
TRAIL in U20S cells.

The Cathepsin B Inhibitor, CA074Me, Protects U20S Cells from TRAIL-mediated
Apoptosis by Delaying the Cleavage of Bid

Our finding that Bid is cleaved before procaspase-8 also implies that a protein
other than caspase-8 cleaves Bid following the exposure of U20S cells to TRAIL.
Cathepsin B belongs to a family of proteases that reside within the acidic environment of
lysosomes.

The involvement of cathepsins in apoptosis is well documented in the

literature and they have been shown to act upstream of the mitochondria in a number of
cellular models (78). Recent studies demonstrate that cathepsin B can contribute to TNFand TRAIL-mediated apoptosis in human cells and that Bid is a target of this lysosomal
protease (66, 68).
To determine whether cathepsin B activity increased in response to TRAIL
treatment, we measured the activity of cathepsin B in lysates from U20S cells treated
with TRAIL/CHX for 0, 0.5, 1 and 2 h. We observed a significant increase in the activity
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Figure 14. TRAIL-induced apoptosis is not mediated by INK or ceramide. (A) Response
of U20S cells to CHX alone, CHX plus TRAIL (50 ng/ml), or CHX, TRAIL and
SP600125 (50 pM). (B) Response of U20S cells pretreated with vehicle (DMSO) or the
indicated concentration of myriocin to TRAIL (2 ng/ml) and CHX. (C) Response of
U20S cells pretreated with the indicated concentrations of desipramine to TRAIL (2
ng/ml) and CHX.
(D) Response of U20S cells pretreated with the indicated
concentrations of imipramine to TRAIL (2 ng/ml) and CHX. For A, B, C and D,
treatment with TRAIL and CHX was performed for 16 h. After 16 h, cell viability was
determined by the MTT assay. Each data point represents three independent replicates,
and the error bars represent the standard deviation.
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of cathepsin B 1 h and 2 h following exposure to TRA1L/CHX (Figure 15A). We then
investigated the contribution of cathepsin B to the TRAIL pathway in U20S cells by
pretreated the cells with CA074Me, a cell permeable inhibitor of cathepsin B, and
assessing the sensitivity of the cells to TRAIL and anti-DR5. We found that CA074Me
provided dose-dependent protection to U20S cells from both TRAIL- and anti-DR5mediated apoptosis (Figure 15B and C). Next, we examined the effect of CA074Me on
TRAIL-mediated Bid cleavage. U20S cells were incubated with CA074Me or vehicle
(DMSO) for 3 h and then treated with TRAIL/CHX for 0, 2 and 4 h. Subsequently, the
cells were lysed and the levels of Bid and PARP in the cell lysates were analyzed by
immunoblot. As expected, Bid and PARP were almost completely cleaved after 2 h of
exposure to TRAIL (Figure 15D).

Intriguingly, the levels of Bid and PARP in the

CA074Me-treated cells appeared to be unchanged at 2 h and overall the levels of these
proteins were higher in the CA074Me-treated cells than in the vehicle treated cells
(Figure 15D). However, there was a significant decrease in the levels of Bid and PARP
between 2 and 4 h (Figure 15D) suggesting that the CA074Me delays, but does not
prevent, the cleavage of Bid.

Together, these findings demonstrate that cathepsin B

mediates TRAIL-induced apoptosis in U20S osteosarcoma cells by cleaving Bid and
precipitating the downstream events in the pathway.
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Figure 15. The cathepsin B inhibitor, CA074Me, protects U20S cells from TRA1Lmediated apoptosis by delaying the cleavage of Bid. (A) Cathepsin B activity assay.
U20S cells were treated with TRAIL (50 ng/ml) in combination with CHX for the
indicated time intervals and then lysed. Subsequently, the lysates were incubated with
the flourogenic substrate for cathepsin B (Z-RR-AMC) in the presence or absence of the
cathepsin B inhibitor, CA074. The released fluorochrome was measured with a
fluorimeter. Percent cathepsin B activity was calculated by subtracting the activity in
wells containing inhibitor from the activity in wells lacking inhibitor and expressing this
number as a percentage of caspase activity in wells containing untreated cells. Each data
point represents three replicates, and the error bars represent the standard deviation. *P <
0.05; **P < 0.01 versus cathepsin B activity of U20S cells at 0 h. (B) Response of U20S
cells pretreated with vehicle (DMSO) or the indicated concentrations of CA074Me to
TRAIL (2 ng/ml) and CHX. (C) Response of U20S cells pretreated with vehicle
(DMSO) or the indicated concentrations of CA074Me to anti-DR5 (50 ng/ml) and CHX.
(D) Cleavage kinetics of Bid and PARP in U20S cells pretreated with vehicle (DMSO)
or CA074Me after exposure to TRAIL (50 ng/ml) and CHX. The expression of Bid and
PARP was analyzed by immunoblot and p-actin expression was used a loading control.
Since the cleavage product of Bid could not be detected, decreases in the amount of fulllength Bid were monitored.
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Discussion

Since its discovery 11 years ago, TRAIL has received a lot of attention because of
its ability to selectively kill cancer cells while sparing normal cells. However, after more
that a decade of research on the mechanisms of TRAIL-mediated apoptosis in human
cells, many questions remain unanswered.

It is not known, for example, why most

normal cells (and some cancer cells) resistant to TRAIL while the majority of cancer cells
are sensitive; or, what other proteins participate in TRAIL-mediated apoptosis besides the
usual suspects (i.e., FADD, caspase-8, etc.). Recent revelations about the mechanisms of
TRAIL-induced apoptosis in different cellular models have begun to unravel some of
these unanswered questions.
Our study provides strong evidence of a mostly FADD-/caspase-8-independent
mechanism of death induced by TRAIL in U20S osteosarcoma cells. We show that in
these cells, TRAIL-induced apoptosis is not impaired in the presence of HPV 16 E6,
which mediates the degradation of both FADD (29) and caspase-8 (Filippova et al.,
manuscript in preparation). Furthermore, we demonstrate that knockdown of FADD and
caspase-8 protein expression by siRNA is not sufficient to prevent TRAIL-induced
apoptosis in U20S cells. The role of FADD and caspase-8 in the TRAIL pathway was a
subject of considerable debate in the years following the discovery of TRAIL.

One

frequently cited publication that provided evidence of a FADD-independent mechanism
of TRAIL-induced apoptosis was the report by Yeh and coworkers. In their report, the
authors demonstrated that MEFs lacking FADD (-/-) could still undergo apoptosis
induced by transient transfection of DR4 (59). In a subsequent study, Kuang et al, who
claimed to use a more physiological approach, demonstrated that FADD-deficient MEFs
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stably transfected with mouse or human DR4/5 were resistant to TRAIL-induced cell
death (79). That same year, two seminal publications, one by Kischkel et al. and the
other by Sprick et al. showed that both FADD and caspase-8 are recruited to the TRAIL
DISC in untransfected cells (7, 8), temporarily quieting the debate over the role of these
proteins in the TRAIL pathway. However, recent publications such as the study by Petak
and colleagues which demonstrates that TRAIL can induce cell death in human
rhabdomyosarcoma cells in a capase-8-independent manner (65), have keep the debate
alive. Our study goes a step further by showing that TRAIL can induce apoptosis in
U20S cells lacking both FADD and capase-8 by two independent methods: E6 and RNA
interference. Thus, our findings support the notion that TRAIL-mediated apoptosis is
cell/tissue type-dependent because E6 inhibits cell death induced by TRAIL in HCT116
cells (69), but not U20S cells.
The absence of a strong correlation between receptor expression and sensitivity to
TRAIL suggests that mostly internal rather than external factors modulate cellular
responses to TRAIL. We have found that U20S cells are more sensitive to TRAIL than
HCT116 cells under the same conditions of TRAIL/CHX treatment, although HCT116
cells express higher levels of DR4 and DR5 than do U20S cells. This observation may
be indicative of the differential regulation of internal modulators of cell death such as Xlinked inhibitor of apoptosis protein (XIAP). In some melanoma cell lines, for example,
XIAP-mediated repression of caspase-3 activity is associated with resistance to TRAILinduced apoptosis (80). However, in TRAIL sensitive melanoma cells, mitochondrial
activation leads to the production of second mitochondria-derived activator of caspases
(Smac/DIABLO) which inhibits the action of XIAP (81). Since the levels of XIAP are
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virtually equivalent between TRAIL sensitive and resistant melanoma cells, the ratio of
Smac/DIABLO to XIAP in these cells following the initiation of the TRAIL pathway
may determine their fate (32).

Other proteins such as FADD-like interleukin-1 P-

converting enzyme-inhibitory protein (cFLIP) and nuclear factor kappa- B (NF-kB) have
been reported to influence cellular sensitivity to TRAIL, but many of these studies have
yielded contradictory results (82).
Another protein that has been linked to TRAIL-mediated apoptosis in some
cellular models is JNK. TRAIL can activate the JNK pathway (62) and there is strong
evidence that JNK can transmit apoptotic signals emanating from TRAIL (63). In this
context, JNK signal transduction leads to the activation of the mitochondrial apoptotic
pathway either by the transactivation of pro-apoptotic genes such as Bax or direct
phosphorylation of anti-apoptotic proteins such Bcl-2 (83) and Bcl-xL (84). Intriguingly,
several studies have found that JNK deficiency can result in defects in thymocyte
apoptosis (85, 86) which is believed to be mediated by TRAIL. Furthermore, it was
shown that mice expressing a dominant negative form of FADD (FADD-DN) or mice
lacking caspase-8 due to the expression of the CrmA transgene did not have any
abnormalities in negative selection (87, 88).

Our results show, however, that pre

incubating U20S cells with a potent and highly selective inhibitor of JNK does not
protect the cells from TRAIL. This finding implies that JNK is dispensable for TRAILinduced apoptosis in U20S cells.
Like JNK, ceramide and other sphingolipid species have been reported to
participate in TRAIL-mediated apoptosis in some cell types. Although the mechanisms
of ceramide-mediated apoptosis have not been fully elucidated, the mitochondria is
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believed to play important role in this process. Recently, it was reported that defects in
ceramide signaling are associated with resistance to TRAIL in metastatic colon cancer
cells.

In another study, it was found that inhibiting sphingosine kinase protects

rhabdomyoscaroma cells from TRAIL-induced apoptosis (65). A subsequent publication
the same group demonstrated that COX-2 inhibitors sensitize colon cancer cells to
TRAIL by modulating ceramide levels (89). We used two approaches to inhibit ceramide
synthesis. First we blocked the de novo synthesis of ceramide with myriocin (ISP-1) and
second, we used imipramine and desipramine to inhibit the activity of sphingomylinase,
an enzyme that converts sphingomyline to ceramide. None of these inhibitors prevented
apoptotic signaling by TRAIL in U20S cells, which suggests that the ceramide pathway
is not a major mediator of TRAIL-induced apoptosis in these cells.
Our study provides evidence that the activation of Bid is the limiting step in the
TRAIL pathway in U20S cells. Not only is Bid cleaved upstream of caspase-8 activation
in these cells but knockdown of Bid by siRNA provides significant protection from
TRAIL-induced apoptosis. The ability of the cathepsin B inhibitor, CA074Me, to protect
U20S cells from TRAIL and delay the cleavage of Bid strongly suggests that cathepsin B
functions upstream of Bid cleavage and plays and important role in the TRAIL pathway
in U20S cells. Indeed, treatment of U20S cells with TRAIL results in a significant
increase in the activity of cathepsin B.

Interestingly, U20S cells incubated with

CA074Me had higher levels of Bid than cells incubated with vehicle, which implies that
cathepsin B is constitutively active even in the absence of signals from TRAIL.
Like cathepsin B, capthepsin D has been shown to influence death receptor
signaling (66, 67). It is possible that cathepsin D also contributes to TRAIL-induced
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apoptosis in U20S cells because the cathepsin D inhibitor, pepstatin A, provides some
protection from TRAIL (data not shown). However, we do not know what events take
place between the ligation of DR4/5 by TRAIL and cathepsin B/D activation. Whether
these events in U20S cells involve novel adaptor molecules and proteases remains to be
seen. So far, none of the usual suspects that we have investigated (i.e., TRADD, TRAF2, RIP and caspase-10) (data not shown) appear to mediate this process.
In conclusion, we have shown by two independent methods (stable transfection of
E6 and RNA interference) that TRAIL can induce apoptosis in U20S cells by a mostly
FADD-/caspase-8-independent pathway. This is in contrast to the case of HCT116 cells,
which require both FADD and caspase-8 for apoptotic signaling by TRAIL.

The

cleavage of Bid is an essential event in the TRAIL pathway in U20S cells, and occurs
well before the activation of caspase-8. The ability of CA074Me to inhibit TRAILmediated apoptosis and delay the cleavage of Bid implies that in these cells, Bid is a
target of the lysosomal protease cathepsin B. Finally, these findings strongly suggest that
TRAIL activates different pathways to apoptosis in a manner dependent on cell type.
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Materials and Methods
Reagents

Lyophilized human recombinant Apo2L/TRAIL (Peprotech Inc., Rock Hill, NJ)
and anti-Fas monoclonal antibodies (clone CH-11) (Medical and Biological Laboratories
Co. Ltd., Nagoya, Japan) were dissolved in phosphate-buffered saline (PBS) to yield 100
pg/ml and 500 pg/ml stocks, respectively; cycloheximide (Sigma, St. Louis, MO) was
prepared as a 5 mg/ml stock; doxycycline (Clontech, Palo Alto, CA) was dissolved in
PBS to yield a 1 mg/ml stock; Z-VAD-FMK (Biomol, Plymouth Meeting, PA) and
CA047Me (Peptide Institute, Inc., Osaka, Japan) were dissolved in dimethyl sulfoxide
(DMSO) to yield 10 mM stocks; SP600125 (Calbiochem) was dissolved in DMSO to
yield a 4 mg/ml stock; Myriocin (ISP-1) (Biomol) was dissolved in DMSO to yield a 5
mg/ml stock; and Z-RR-AMC (Biomol) and CA074 (Biomol) were dissolved in DMSO
to yield 20 pM stock solutions. Each of these reagents were aliquoted and stored at 20°C prior to use. 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
(Sigma) was dissolved in PBS to yield a stock concentration of 5 mg/ml, while
Desipramine (Sigma) and tmipramine (Sigma) were dissolved in water to yield 10 mM
stocks. All three stock solutions were stored at 4°C until use.
Monoclonal antibodies directed against p-actin and HA (Roche Molecular
Biochemicals), were dissolved in PBS to yield 400 pg/ml stock solutions and stored at 20°C before use.

The mouse monoclonal, rabbit polyclonal and rat polyclonal

peroxidase-coupled anti-HA antibodies (Roche Molecular Biochemicals) were stored
under the same conditions prior to use.

Other antibodies used included antibodies
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directed against Bid (BD Phanningen), caspase-3 (Transduction laboratories), caspase-8
(Alexis

Biochemicals),

green

fluorescence

protein

(GFP)

(Roche

Molecular

Biochemicals), Lamin B (Santa Cruz Biotechnology) and PARP (Calbiochem). We also
used monoclonal (HS101) and polyclonal DR4 antibodies (Alexis Biochemicals) and
monoclonal (HS201) and polyclonal DR5 antibodies (Alexis Biochemicals). All of these
antibodies were stored at 4°C until use with the exception of the DR4 and DR5
monoclonal antibodies which were kept at -20°C.

Cell Culture

HCT116 (human colon carcinoma) cells and U20S (human osteosarcoma) cells
were obtained from the ATCC (Manassas, VA) and were cultured in McCoy's 5A
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(Invitrogen), penicillin (100 U/ml), and streptomycin (100 pg/ml) (Sigma).

Plasmids

The pHA-E6S and pHA-E6AS plasmids have been described previously (29), and
respectively contain either the sense or the antisense versions of epitope-tagged E6 (HAE6) under the control of the CMV promoter. pcDNA3-FADD was kindly provided by
Dr. Carl Ware (La Jolla Institute for Allergy and Immunology, La Jolla, CA). pEGFP-1
was purchased from Clontech Laboratories, Mountain View, CA and a CMV promoter
construct was cloned into its multiple cloning site for constitutive expression of GFP.
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Transfections

Transfections (except with siRNA) were carried out using FuGENE VI (Roche
Molecular Biochemicals), as directed by the manufacturer. For transient transfections,
cells were analyzed 40-48 h post-transfection.

For stable transfections, clones were

passaged into selection medium containing G418 (500 pg/ml) 72 h post-transfection.
Individual clones were selected, grown and analyzed for protein expression by
immunoprecipitation and immunoblotting.

Treatment of Cells with TRAIL, anti-Fas, Cycloheximide, Z-VAD-FMK, SP600125,
Myriocin, Desipramine, Imipramine and CA074Me

To measure cell survival following treatment with TRAIL and anti-Fas, cells were
seeded in a 96-well plate (1- 2 x 104 cells/well) and allowed to adhere overnight. TRAIL
(at the concentrations noted in the figure legends) and anti-Fas (50 ng/ml) were then
added in the presence of CHX (5 pg/ml) and the cells were incubated for 16 h prior to
measuring the number of viable cells by the MTT assay. To determine whether cell death
following

TRAIL treatment was

caspase

dependent,

cells were

treated with

cycloheximide (5 pg/ml) and TRAIL in the presence or absence of Z-VAD-FMK (50
pM) for 16 h. Cell viability was measured by the MTT assay.
To assess the response of U20SE6tet24 cells (29) to TRAIL and CHX, the cells
were grown in the indicated concentrations of doxycycline for 2 days and then seeded in
a 96~well plate at 2 x 104 cells/well and allowed to adhere overnight. The following day,
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the cells were treated with CHX alone or CHX plus TRAIL in the indicated
concentrations of doxycycline/media for 16 h.

Subsequently, cell viability was

detennined by the MTT assay.
To examine the cleavage kinetics of Bid, capase-8, caspase-3, Lamin B and
PARP, cells were seeded in 6-well plates at 2 x 105 cells/well and allowed to adhere
overnight. The following day, cells were treated for the indicated times (refer to
individual experiments) with CHX (5 pg/ml) and TRAIL. In experiments that required
pretreatment of cells with a particular reagent, pretreatment was performed for no less
than 3 h. Following treatment with CHX and TRAIL, the cells were lysed and the
proteins of interest in the lysates were analyzed by immunoblot.
To determine effect of SP600125, myriocin, desipramine, imipramine and
CA074Me on TRAIL-mediated cell death, cells were seeded in a 96-well plate at 2 x 104
cells/well, allowed to adhere overnight, and then pretreated for no less than 3 h with the
indicated reagents or vehicle (i.e., water or DMSO) at the concentrations noted in the
figure legends.

Subsequently, the cells were treated with CHX only or CHX plus

TRAIL. After incubation for 16 h at 37°C, cell viability was measured by the MTT
assay.

Cell Viability Assay

Following treatment of cells as described above, the incubation medium was
removed and exchanged with 80 pi of fresh medium. Twenty microliters of MTT was
then added (5 mg/ml stock), and cells were incubated at 37°C for 3 h. The medium was
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removed, and 150 \i\ of DMSO was added and allowed to incubate for 10 min. Afterward,
the solution was mixed by pipetting, and the absorbance of each well was measured at
490 nm.

Immunoblotting

Cells (2 x 106) were lysed in 100 pi of lysis buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% Triton X-100, 1 mM EDTA, 5% glycerol, 1 mM DTT, 1 mM PMSF) for
10 min on ice. One tablet of protease inliibitor mixture (Roche Applied Science) per 10
ml of lysis buffer was added just prior to use. The protein concentration in cleared lysates
was measured using the Bio-Rad Protein Assay (Bio-Rad).
Lysates (40 pg total protein/lane) were then subjected to 12% SDS-PAGE and
transferred to Immobilon P membranes (Millipore Corp.). After treating the membranes
with 5% nonfat milk in TBST (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween 20),
primary antibodies were applied and membranes were incubated for 1 h, with rocking, at
room temperature. After washing with TBST, peroxidase-coupled secondary antibodies
were added for detection. The membranes were then washed again with TBST following
1 h of incubation in the secondary antibodies. Detection of the proteins was performed by
using the chemiluminescent SuperSignal West Femto or Pico Maximum Sensitivity
substrate (Pierce).
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Immunoprecipitation

Cells (2-5 x 106) were lysed in 500 fil of the immunoblotting lysis buffer, and
cleared lysates were incubated with 2 jig of monoclonal anti-HA antibody (Roche
Molecular Biochemicals) at 4°C for 1 h with rotation. Protein A/G-agarose slurry (50 gl)
(Santa Cruz Biotechnology, Santa Cruz, CA) was added to each lysate, and lysates were
incubated for 2 h at 4°C. The protein A/G slurry was then washed three times with lysis
buffer, followed by one wash with high salt buffer (50 mM Tris-HCl, pH 7.5, 0.5 M
NaCl, 0.1% Nonidet P-40, 1 mM EDTA, 1 mM DTT) and one wash with the same buffer
lacking NaCl.

The precipitates were fractionated by

12%

SDS-PAGE, and

immunoblotting was performed as described above.

Morphological Analysis ofApoptotic Cells

Cells were seeded on coverslips in a 6-well plate and allowed to incubate
overnight. The following day, cells were treated with 50 ng/ml TRAIL for 2 h, 50 ng/ml
anti-DR5 monoclonal antibodies for 6 h or 50 ng/ml anti-Fas antibodies for 6 h. All
treatments were performed in the presence of CHX (5 pg/ml). After the indicated time
points, the cells were fixed in a solution of 4% paraformaldehyde/PBS for 15 min at room
temperature, washed 3 times with PBS, and then mounted on glass slides using
Vectashield mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Inc. Burlingame, CA). The morphology of the cells was then analyzed by
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phase-contrast microscopy (Olympus BX50, Japan).

DAPI-stained nuclei were

monitored using the UplanFI objective at a magnification of 1000X.

Flow Cytometry

FACS analysis was performed according to the method of Kischkel et al (8) with
modifications. Cells (1 x 106) were detached with Cellstripper (Mediatech, Inc., Herdon,
VA), washed once with PBS, and then resuspended in 1 ml of cold buffer (lx PBS, 3%
BSA, 0.1% azide) containing 10 pg/ml anti-DR4 (HS101) or anti-DR5 (HS201). After
incubation for 60 min on ice, cells were washed 3 times with cold buffer, and incubated
with FITC-conj ugated secondary antibody (goat anti-mouse IgG FITC) (BD Biosciences)
diluted 1: 100. Staining with the secondary antibody was performed for 60 min at 4°C in
the dark. Subsequently, cells were washed 3 times with cold PBS and 10,000 cells per
sample were analyzed using a FACSCalibur (BD Biosciences). The resulting data was
analyzed with the FlowJo software package (Tree Star Inc., Ashland, OR).

SiRNA Experiments

Transfection of cells with siControl (random sequence) (Dharmacon Research,
Inc., Lafayette, CO), siBid (Santa Cruz Biotechnology), siCaspase-8 (Santa Cruz
Biotechnology) and siFADD (Santa Cruz Biotechnology) was performed according to the
manufacturer’s protocol.

Briefly, cells were seeded in media lacking antibiotics and

incubated at 37°C overnight. The transfection mixtures were then prepared by adding
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siRNA to siTransfection Medium (Santa Cruz Biotechnology) in one tube and
siTransfection Reagent (Santa Cruz Biotechnology) to siTransfection Medium (Santa
Cruz Biotechnology) in another tube and incubating the contents of the tubes at room
temperature for 5 min. The amounts of the reagents were calculated based on the values
indicated in the protocol and were scaled up or down in proportion to the surface area of
the plate. After 5 min, the mixtures were combined and incubated at room temperature
for 20 min to facilitate the development of a siRNA-siRNA transfection reagent complex.
During this time, the media covering the cells was replaced with fresh media without
antibiotics and at the end of the 20 min incubation, the complex was added to the cells.
The cells were then incubated at 37°C for 24-30 h.
To verify that the indicated siRNAs were knocking down the expression of their
target proteins, cells were seeded in a 6-well plate at a density of 2.5 x 105 cells/well and
transfected with the specific siRNAs or siControl as described above. The siFADD
transfected cells were also transfected with pcDNA3-FADD and pE-lCMV-GFP 24 h
after the first transfection. All transfected cells were then incubated for 24-48 h at 37°C.
The protein expression of Bid, caspase-8 and FADD was then analyzed by immunoblot.
To measure the effect of TRAIL on the survival of cells transfected with
siControl, siBid, siCaspase-8 and siFADD, cells were seeded in a 96-well plate at a
density of 1.8 x 104 cells/well and transfected with the indicated siRNAs as described
above. The cells were then treated with TRAIL (50 ng/ml) in the presence of CHX (5
pg/ml) for 16 h and cell viability was detennined by the MTT assay.
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Caspase-8 Activity Assay

Cells were plated into black 96-well plates at a density of 2 x 104 cells per well
and incubated overnight. TRAIL (50 ng/ml) was then added, along with cycloheximide (5
pg/ml) at the indicated time points. Caspase activity was then measured using the
flourogenic substrate IETD-AMC for caspase-8 (Alexis Biochemicals) as previously
described (51). Briefly, cells (in a total volume of 40 pi media/well) were lysed by the
addition of 20 pi of 3X lysis buffer (150 mM HEPES, pH 7.4, 450 mM, NaCl, 150 mM
KC1, 1.2 mM EGTA, 1.5% Nonidet P40, 0.3% CHAPS, 30% sucrose, 30 mM DTT, 3
mM PMSF) which included either substrate alone (150 pM) or substrate plus inhibitor
IETD-CHO (BD Pharmingen) (2 pg/ml). After 2 and 4 h of incubation, the released
fluorochrome was measured with a plate-reading fluorimeter (Flx800, Bio-Tek
Instrument Co) using an excitation of 360 nm and an emission of 460 nm. The activity in
wells treated with inhibitor was subtracted from the activity in wells lacking inhibitor.
The resulting difference was expressed as a percentage of the caspase activity of the
untreated cells.

Cathepsin B Activity Assay

Cathepsin B activity was measured according to the method of Nagaraj et al. (68)
with modifications. Briefly, U20S cells were seeded in a 6-well plate at a density of 5 x
105 cells/well. Subsequently, the cells were not treated or treated with TRAIL (50 ng/ml)
in the presence of CHX for 0.5, 1, and 2 h. After treatment, the cells were washed with
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cold PBS, treated with lysis buffer (100 mM K-phosphate, 150 mM NaCl, 4 mM EDTA,
0.25% Triton X-100, pH 6.0) for Ih on ice, sonicated and centrifuged.

Following

centrifugation, the supernatants were removed and added in triplicate to a 96-well plate.
For each time point, lysates were treated with either substrate alone (Z-RR-AMC) (200
pM) or substrate plus inhibitor (CA074) (50 pM), and incubated on a shaker for 1-2 h at
37°C. Fluorescence was measured 2 h and 24 h after treatment. The activity in wells
treated with inhibitor was subtracted from the activity in wells lacking inhibitor. The
resulting difference was expressed as a percentage of the cathepsin B activity of the
untreated cells.

Statistical Analysis

Data were analyzed using the unpaired t test on a GraphPad Prism software
package for Windows (GraphPad Software Inc.). A P value of <0.05 was considered
statistically significant.
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CHAPTER FOUR
UNPUBLISHED RESULTS
Introduction
The experiments described in this chapter were performed to fulfill the specific
aims of the study, but have not yet been included in manuscripts derived from the study.
Nevertheless, the results of these experiments provide additional insight into the main
questions addressed by the study.

Methods
(i.e., not included in previous chapters)
Mammalian Two-Hybrid Assay
The mammalian two-hybrid binding assay was performed according to the
manufacturer's instructions (Clontech). The indicated combinations of vectors were
transfected into U20S cells (5 x lO/well, 6-well plates) along with a luciferaseexpressing reporter plasmid using FuGENE 6 (Roche Applied Science) as directed by the
manufacturer. Forty-eight h following transfection, luciferase activity was measured with
a luminometer using a commercially available luciferase detection kit (Promega) as
directed by the manufacturer.

Results
TRAIL Receptor Expression and Interactions
As shown in chapter 3, HCT116 and U20S cells express different levels of DR4
and DR5. The levels of these receptors are higher on HCT116 cells than on U20S cells,
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Figure 16. Effect of various siRNAs on the sensitivity of HCT116 and U20S cells to
TRAIL. HCT116 and U20S cells were transfected with the indicated siRNAs as
described in chapters 2 and 3. The cells were then treated with TRAIL (50 ng/ml) and/or
anti-Fas (50 ng/ml) in the presence of CHX. Cell viability was measured by the MTT
assay. Each data point represents three independent replicates and the error bars
represent the standard deviation. (A) HCT116 and U20S cells; 50 ng/ml TRAIL. (B)
HCT116 cells; 50 ng/ml TRAIL. (C) U20S cells; 50 ng/ml TRAIL and anti-Fas.
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which appear to express very low levels of both receptors.

These findings were

confirmed by examining the effect of inhibiting DR4 and DR5 expression on the
sensitivity of HCT116 and U20S cells to TRAIL, in a series of experiments using siRNA
to target these receptors (Figure 16). In general, we found that transfection of siRNA
targeting DR4 (Figure 16A) and DR5 (Figure 16B) into HCT116 cells caused the cells to
be more resistant to TRAIL. However, while inhibiting the expression of DR5 protected
U20S cells from TRAIL (Figure 16C), no such protection was observed when DR4
expression was inhibited (Figure 16A and C).

The latter is consistent with our

observation in chapter 3 that TRAIL induces apoptosis primarily through DR5 in U20S
cells.
We then examined the interaction between DR4/DR5 and FADD using a
mammalian two hybrid assay. Intriguingly, we found that DR4, but not DR5 interacts
with FADD (Figure 17A). This finding contrasts with those from studies that have
demonstrated the interaction of DR5 and FADD by co-immunoprecipitation and/or
mammalian two-hybrid techniques (Kischkel et al., 2000, Sprick et al., 2000, Thomas et
al., 2006). We also examined whether E6 could disrupt the interaction between DR4 and
FADD. We found DR4 and FADD could interact at low levels of E6 but not at high
levels (Figure 17B). To our knowledge, the interaction between DR4 and E6 has not
been previously reported and therefore, DR4 is potentially a new E6 binding partner.
These findings, together with those from chapter 2, demonstrate that E6 targets at least
three different proteins (DR4, FADD, and caspase-8) in the TRAIL signaling pathway.
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Figure 17. TRAIL receptor-FADD interactions. (A) FADD binds to the death domain of
DR4, but not DR5. U20S cells were transfected with the indicated combinations of
mammalian two-hybrid vectors coding for DR4, DR5, TNFR1, FADD, TRADD, and
caspase-8, as well as with a luciferase reporter plasmid. The level of interaction of the
resulting proteins was determined by measuring luciferase activity. Values greater >3
RLU were considered significant. (B) E6 disrupts the binding of FADD to DR4. U20S
cells containing E6 under the control of a doxycycline-inducible promoter (#24) or cells
only expressing the tet regulator (B7) were co-transfected with mammalian two-hybrid
vectors coding for DR4 or FADD in both orientations, as well as with a luciferase
reporter plasmid. Changes in the interaction between DR4 and FADD were monitored by
measuring luciferase activity.
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Alternative Adaptor Molecules and Proteases in the TRAIL Pathway
Our finding in chapter 3 that FADD and caspase-8 are not the primary mediators
of the TRAIL pathway in U20S cells led us to speculate about what other adaptor
molecules and caspases may be involved in the apoptotic cascade induced by TRAIL in
these cells. Using siRNA, we selectively inhibited the expression of number of candidate
adaptor molecules such as TRADD, TRAF2, and RIP, and then examined the effect of
inhibiting their expression on the sensitivity of U20S cells to TRAIL (Figure 18). We
found that transfection of siRNA targeting TRADD (Figure 18A), TRAF2 (Figure 18A),
and RIP (Figure 18B) into U20S cells did not protect the cells from TRAIL-mediated
apoptosis, although some protection was observed following co-transfection of these cells
with FADD (control) and TRADD (Figure 18A). These results provide strong evidence
that siTRAF-2 and siRIP do not participate in the TRAIL pathway in U20S cells. In
addition, while the effect of siFADD and siTRADD (together) on TRAIL-induced cell
death is interesting, neither siFADD nor siTRADD alone significantly inhbited apoptosis
mediated by TRAIL in U20S cells (Figure 18 A).
We also examined the role of caspase-10 and caspase-2 in the TRAIL pathway in
U20S cells (Figure 19). We found that transfection of siRNA targeting caspase-10 into
U20S cells did not provide protection from TRAIL-induced apoptosis (Figure 19A). In
the case of caspase-2, treatment of U20S cells with TRAIL increased its activity (Figure
19B; white bar); however, even though this activity was inhibited in the presence of E6
(Figure 19B; black bar) the resulting decrease in caspase-2 activation did not correlate
with a change in the sensitivity of the cells to TRAIL. Finally, to determine whether
cathepsin D might also play a role in the TRAIL pathway in U20S cells (chapter 3) we
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Figure 18. Alternative adaptor molecules in the TRAIL pathway. U20S cells were
transfected with the indicated siRNAs as described in chapters 2 and 3. The cells were
then treated with TRAIL (50 ng/ml) or anti-Fas (50 ng/ml) in the presence of CHX. Cell
viability was measured by the MTT assay after 16 h. Each data point represents three
independent replicates and the error bars represent the standard deviation. (A) Effect of
siFADD (control), siTRADD, and siTRAF-2 on the sensitivity of U20S cells to 50 ng/ml
TRAIL or 50 ng/ml anti-Fas. (B) Effect of siBid (control) and siRIP on the sensitivity of
U20S cells to 50 ng/ml TRAIL or 50 ng/ml anti-Fas.
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pretreated the cells with a potent inhibitor of cathepsin D known as pepstatin A. We
found that pepstatin A provided some protection from TRAIL at concentrations similar to
those used to determine the effect of CA074Me on TRAIL-induced cell death (Figure
19C). Therefore, it is possible that both cathepsin B and D may contribute to apoptotic
signaling by TRAIL in U20S cells.

Conclusions
The results of the experiments described in this chapter provide additional
evidence in support of the conclusions in chapters 2 and 3. Indeed, our discovery that E6
binds to DR4 is novel and bolsters our findings regarding the ability of E6 to disrupt the
TRAIL apoptotic signaling pathway. The role of caspase-10, TRADD, RIP, and TRAF-2
in the TRAIL pathway has been debated in the literature. Our results suggest that these
proteins do not play a significant role in the TRAIL pathway in U20S cells. Finally, our
results provide evidence that in U20S cells cathepsin D may also contribute apoptotic
signaling by TRAIL.
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Figure 19. Involvement of caspase and non-caspase proteases in the TRAIL pathway in
U20S cells. (A) Caspase-10 does not contribute to TRAIL-mediated apoptosis in U20S
cells. U20S cells were transfected with the indicated siRNAs as described in chapters 2
and 3. The cells were then treated with TRAIL (50 ng/ml) in the presence of CHX. Cell
viability was measured by the MTT assay. (B) Caspase-2 activity is enhanced by TRAIL
and suppressed by E6 in U20S cells. The caspase-2 activity assay was performed as
described in chapter 2 after treatment of the U20SE6AS9 and U20SE64b cells with 50
ng/ml TRAIL/CHX for the indicated time periods. (C) The cathepsin D inhibitor,
pepstatin A, moderately protects U20S cells from TRAIL. U20S cells were pretreated
with the indicated concentrations of pepstatin A for 24 h, then treated with 2 ng/ml
TRAIL in the presence of CHX. Cell viability was measured by the MTT assay.
P<
0.001 versus U20S cells pretreated with 0 pM pepstatin A. For A, B, and C, each data
point represents three independent replicates and the error bars represent the standard
deviation.
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CHAPTER FIVE
DISCUSSION
Summary of Findings
This study examined the influence of HPV 16 E6 on the TRAIL apoptotic
pathway.

An understanding of this pathway is very important because of TRAIL’S

putative role in immune surveillance, as well as its potential use as an anticancer drug.
Our discovery that E6 abrogates TNF- and Fas-mediated apoptosis (Filippova et al.,
2004, Filippova et al., 2002) suggested that E6 would be an attractive candidate to
examine the molecular mechanisms of the TRAIL pathway because TNF, Fas, and
TRAIL share a common signaling mechanism. As predicted, our results have elucidated
an alternative cell death pathway utilized by TRAIL and have provided new insights into
the role of E6 as a viral mechanism of immune evasion.
The results of the experiments in chapter 2 convincingly demonstrate that E6
protects human epithelial HCT116 cells from TRAIL-induced apoptosis in a dosedependent manner because higher levels of E6 provided greater protection from TRAIL.
Furthennore, the TRAIL apoptotic pathway in these cells is dependent on FADD and
caspase-8 because cell death induced by TRAIL was significantly inhibited in cells
expressing E6, and we have shown that E6 mediates the degradation of both FADD
(Filippova et al., 2004) and caspase-8 (manuscript in preparation) via the ubiquitinproteosome pathway. While TRAIL-induced apoptosis in HCT116 cells requires the
activation of the mitochondrial pathway to amplify cell death signals from TRAIL, E6
did not protect HCT116 cells from TRAIL by interfering with the mitochondrial
pathway. Rather, E6 accelerated degradation of FADD and caspase-8 which led to the
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suppression of caspase activation and protection from TRAIL-induced cell death. In
contrast, the results of the experiments in chapter 3 show that expression of E6 in U20S
cells does not provide protection from TRAIL-mediated apoptosis. This finding strongly
suggests that TRAIL utilizes a FADD/caspase-8 independent pathway in U20S cells
because the results in chapter 2 demonstrate that E6 protects HCT116 cells from TRAIL
by reducing the half-life of FADD and caspase-8. The possibility that TRAIL induces a
FADD/caspase-8 independent pathway in U20S cells was confirmed by the finding that
TRAIL-mediated apoptosis is not significantly impaired in cells transfected with siRNA
targeting FADD or caspase-8. Rather, siRNA targeting Bid provided strong protection
from TRAIL-induced apoptosis.

In addition, we found that TRAIL-induced Bid

cleavage, as well as TRAIL-induced apoptosis in U20S cells, could be inhibited by a
potent and selective inhibitor of cathepsin B. Together, these results suggest that TRAIL
can trigger distinct apoptotic pathways dependent on the cell type and that FADD and
caspase-8 are not the primary mediators of TRAIL-induced apoptosis in all cases. Thus,
agents that can sensitize cells to TRAIL by enhancing its ability to activate cathepsin B
may possess therapeutic potential. The results also suggest that E6 may only be effective
in blocking TRAIL-mediated apoptosis in cells where the FADD/caspase-8 pathway
predominates, but not in cells in which TRAIL utilizes an alternative (FADD/caspase-8
independent) pathway.

The TRAIL Apoptotic Pathway
The findings of this study, as well as a growing body of evidence, suggests that
the TRAIL apoptotic pathway is much more complex that was previously thought. For

155

example, our study demonstrates that FADD and capase-8 are necessary for TRAILmediated apoptosis in HCT116 cells but may be dispensable for cell death induced by
TRAIL in U20S cells.

These observations are consistent with earlier reports which

provided evidence for and against the involvement of these proteins in the TRAIL
pathway (Chaudhary et al., 1997, Griffith et al., 1998, MacFarlane et al., 1997,
Muhlenbeck et al., 1998, Pan et al., 1997a, Pan et al., 1997b, Schneider et al., 1997,
Sheridan et al., 1997). A number of studies also suggest that TRAIL triggers alternative
(FADD/caspase-8 independent) apoptotic pathways, such as the JNK and ceramide
pathways, in some cell types (Herr et al., 1999, Voelkel-Johnson et al., 2005).

In

addition, our findings and work by others demonstrate that the lysosomal protease
cathepsin B, can participate in the TRAIL apoptotic pathway in some cases (Nagaraj et
al., 2006).

The use of two death receptors (DR4 and DR5) by TRAIL to transmit

apoptotic signals to the nucleus has been a topic of interest to investigators of the TRAIL
pathway. Recent findings suggest that these receptors are not redundant in function as
many investigators believed. For example, Leverkus et al. reported that DR4 (TRAILRl) was more efficient than DR5 (TRAIL-R2) in the induction of apoptosis, caspase
activation and NF-kappa B activation in HaCat keratinocytes (Leverkus et al., 2003). In
another study, Kelley and coworkers found that DR5-selective mutants of TRAIL were
more efficient than their DR4 counterparts in triggering apoptosis in cancer cells that
express both DR4 and DR5 (Kelley et al., 2005). Finally, a third study demonstrated that
a mouse anti-human DR5 monoclonal antibody (anti-DR5 Mab) could trigger a different
apoptotic pathway than that induced by TRAIL in jurkat cells and that the binding sites of
TRAIL and anti-DR5 Mab on the DR5 receptor did not overlap (Guo et al., 2005).
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Together, these studies suggest that the TRAIL apoptotic pathway is multifaceted and
possesses many potential therapeutic targets.

Regulation of Host-mediated Apoptosis by HR-HPV Oncoproteins
HPV, like many of its viral counterparts has developed sophisticated mechanism
to evade host-defenses and establish a successful infection. The primary weapons at its
disposal are the E5, E6 and E7 oncoproteins. Like E6, the E7 oncoprotein of HR-HPVs
is necessary for both cellular transformation and viral pathogenesis. E7’s primary target
is retinoblastoma (Rb) and its related proteins including pi07 and pi30 (Berezutskaya et
al., 1997, Dyson et al., 1989). Under normal conditions, Rb forms a complex with
histone deacetylase (HDAC) and binds to the E2F transcription factor in the G1 phase of
the cell cycle.

This prevents E2F from transactivating genes that are necessary for

proliferation until the cell enters the S phase. However, when E7 is expressed in cells, it
binds to Rb and HD AC and relieves their repression of E2F, resulting in the constitutive
activation of E2F-responsive genes. The actions of E7 cause the cell to reenter the Sphase where cellular replication factors that are necessary for viral replication are
activated. E7 binds to many other proteins as well, including proteins involved in cell
cycle control such as cyclin-dependent kinase (cdk)2 and cyclin A (Tommasino et al..
1993); proteins regulating transcription such as the TATA box-binding protein and the
API transcription factors (Antinore et al., 1996, Massimi et al., 1996, Phillips &
Vousden, 1997); and proteins with other cellular functions such as TAF-110 and TBP
(Mazzarelli et al., 1995), the S4 ATPase of the 26S proteosome (Berezutskaya & Bagchi,
1997), Mi2 (Brehm et al., 1999), Interferon Regulatory Factor-1 (Park et al., 2000),
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IGFBP-3 (Mannhardt et al., 2000), M2-PK (Mazurek et al., 2001), Skip (Prathapam et ak,
2001), and PP2A (Pim et al., 2005).
Besides its role in cell proliferation and viral replication, E7 also regulates
apoptosis.

However, its effect on cellular apoptotic pathways is pleiomorphic.

For

example, in some studies the actions of E7 appear to be antiapoptotic. A case in point is
a recent study by Yuan et al. which suggests that E7 can inhibit TNF-mediated apoptosis
in keratinocytes by upregulating the expression of the inhibitor of apoptosis protein, cIAP2 (Yuan et al., 2005). hi another study, it was reported that the expression of E7 in
fibroblasts delayed Fas-mediated apoptosis and prevented TNF-mediated apoptosis by a
mechanism involving the suppression of caspase-8 activation (Thompson et al., 2001).
However, other studies suggest that E7 can sensitize cells to apoptosis. For example, E7
has been shown to sensitize mouse lymphoma cells (JD3) to IFN-alpha-induced apoptosis
(Thyrell et al., 2005); co-expression of E7 and p21 induced apoptosis in U20S
osteosarcoma cells (Kaznelson et al., 2004); and, overexpression of E7 in genital
keratinocytes induced spontaneous cell death and sensitized the cells to TNF-mediated
apoptosis (Stoppler et al., 1998). The pleiotrophic effect of both E6 and E7 on apoptosis
is indicative of their important role in immune evasion and underscores the complexity of
HPV-host interactions.
The interaction of E6 and E7 with their primary cellular targets, p53 and Rb,
respectively, plays an important role in the initiation of tumorigeneisis, and these
oncoproteins are also required for retaining the transformed status of infected cells
(Longworth & Laimins, 2004). Intriguingly, E6 and E7 can inhibit apoptosis induced by
stimuli such as TNF as well as sensitize cells to TNF and other apoptotic stimuli
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(Filippova et al., 2005, Thompson et al., 2001, Yuan et al., 2005). The significance of
these observations is still being investigated, but clues to their possible role in the viral
life cycle are beginning to unfold. The fact that HPV encodes proteins that perform both
functions (protection/sensitization) suggests that (1) during the viral life cycle both
functions may be required, and/or that (2) E6 can compensate for E7 or vice versa if the
expression of one or the other protein is lost (i.e., through deletion) or silenced (e.g., by
antisense or siRNA molecules produced by the host) during the viral life cycle. Indeed,
while the expression of both E6 and E7 are necessary to efficiently immortalize cells,
they can also induce cell transformation on their own (Berber et al., 1996, Song et al.,
1999). This finding as well as the ability of both proteins to modulate cell survival
suggests that there is some redundancy in their functions. If true, this would be highly
advantageous to the virus as it tries to persist in the host and avoid elimination.
The role of E5 in protecting HPV from elimination by the host has not received
much attention because of its weak transforming properties and the fact that the E5 open
reading frame (ORE) is often deleted after the HPV genome has integrated into the DNA
of the host (DiMaio & Mattoon, 2001, Massimi & Banks, 2005).

Furthennore, direct

immunoblot analysis of E5 protein expression has been hindered by its low solubility and
many studies have utilized tagged versions of the protein for easier analysis. HPV E5 is a
hydrophobic protein and is expressed in cellular membrane structures such as the Golgi
apparatus, endoplasmic reticulum and the nuclear membrane (Conrad et al., 1993). The
exact function of E5 is not known but a number of its actions have been described. For
example, HPV 16 E5 has been reported to interfere with the actin cytoskeleton and block
endocytic trafficking (Thomsen et al., 2000); modulate epidermal growth factor receptor
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signaling (Crusius et al., 1998, Crusius et al., 2000, Pim et al., 1992, Straight et al.,
1993); induce c-jun expression via a ras- and PKC-dependent pathway (Chen et al.,
1996a); trigger the upregulation of diacylglycerol (DAG) and inositol phosphates in
fibroblast cells (Crusius et al., 1999); and decrease the expression of surface HLA class I
molecules (Ashrafi et al., 2005).
With regard to its role in tumorigenesis, E5 has been shown to induce fibroblasts
to form colonies in soft agar (Pim et al., 1992, Straight et al., 1993), increase the
efficiency of immortalization of keratinocytes by E6 and E7 (Stoppler et al., 1996), and
impair cell-cell communication at gap junctions (Oelze et al., 1995).

While these

activities may not be necessary for maintaining the malignant status of infected cells, the
findings of these studies and others suggest that E5 may play an important role in the
initial phase of tumorigenesis. Indeed, prior to integration, when the HPV genome is
episomal, the E5 mRNA is the most abundant viral transcript (Stoler et al., 1992). E5 has
also been reported to inhibit the expression of the p21 tumor suppressor (Tsao et al.,
1996), which suggest that it may co-operate with E6 and E7 to transform keratinocytes.
Interestingly, the E5 protein has been shown to protect HaCat keratinocytes from both
Fas- and TRAIL-mediated apoptosis, albeit by different mechanisms (Kabsch & Alonso,
2002). In their study, Kabsch and Alonso showed that E5 inhibits Fas-induced apoptosis,
in part, by decreasing the cell surface expression of the Fas receptor. While E5 did not
down-regulate TRAIL receptor expression, it was found to inhibit TRAIL signaling by
interfering with the formation of the TRAIL DISC and thereby inhibiting the cleavage of
pro-caspases 8 and 3, as well as of PARP (Kabsch & Alonso, 2002). Therefore, it is
possible that E5 interferes with the ability of the immune system to eliminate infected
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cells by impairing death receptor signaling. Together, the results of these studies provide
strong evidence that the E5 contributes to the evasion of immune surveillance during the
early stages of HPV infection.

Conclusions
In conclusion, this study has demonstrated that E6 can inhibit TRAIL-mediated
apoptosis, but only in cells in which the FADD/caspase-8 pathway predominates. This
finding implies that 1) through the activities of E6, HR-HPV can utilize both p53dependent and -independent mechanisms to inhibit host-mediated apoptosis, and that 2)
TRAIL follows different pathways to apoptosis depending on the cell type. In addition,
the findings of this study, as well as the studies that were reviewed in previous section,
suggest that targeting E5, E6, and E7 is a prudent strategy for therapies aimed at
preventing the development of premalignant intraepithelial lesions and their progression
to cancer.
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